

# International Variation in Prostate Cancer Incidence and

European Urology

61, 1079-1092

DOI: [10.1016/j.eururo.2012.02.054](https://doi.org/10.1016/j.eururo.2012.02.054)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Androgen Metabolism Gene Polymorphisms, Associations with Prostate Cancer Risk and Pathological Characteristics: A Comparative Analysis between South African and Senegalese Men. Prostate Cancer, 2012, 2012, 1-8.	0.6	23
2	Medicinal Properties of the Jamaican Pepper Plant Pimenta dioica and Allspice. Current Drug Targets, 2012, 13, 1900-1906.	2.1	56
3	Overexpression of signal transducer and activator of transcription (STAT-3 and STAT-5) transcription factors and alteration of suppressor of cytokine signaling (SOCS-1) protein in prostate cancer. Journal of Receptor and Signal Transduction Research, 2012, 32, 321-327.	2.5	10
4	Biochemical Recurrence After Robot-assisted Radical Prostatectomy in a European Single-centre Cohort with a Minimum Follow-up Time of 5 Years. European Urology, 2012, 62, 768-774.	1.9	85
5	Active Surveillance for Prostate Cancer: A Systematic Review of the Literature. European Urology, 2012, 62, 976-983.	1.9	518
6	Robot-assisted Radical Prostatectomy – “Fake Innovation or the Real Deal?”. European Urology, 2012, 62, 365-367.	1.9	2
7	Active Surveillance for Prostate Cancer: Barriers to Widespread Adoption. European Urology, 2012, 62, 984-985.	1.9	11
8	“A Robot Saved My Life” Is It a Myth?. European Urology, 2012, 62, 775-776.	1.9	1
9	3p21.3 tumor suppressor gene RBM5 inhibits growth of human prostate cancer PC-3 cells through apoptosis. World Journal of Surgical Oncology, 2012, 10, 247.	1.9	32
10	DNA vaccination for prostate cancer, from preclinical to clinical trials - where we stand?. Genetic Vaccines and Therapy, 2012, 10, 9.	1.5	13
11	Isolated, disseminated and circulating tumour cells in prostate cancer. Nature Reviews Urology, 2012, 9, 448-463.	3.8	32
12	The prostate cancer conundrum revisited: Further insights. Cancer, 2012, 118, 5724-5727.	4.1	6
13	Prostate Cancer Epidemic in Sight?. European Urology, 2012, 61, 1093-1095.	1.9	14
14	Opinions from the Experts: Exploring What Prostate Cancer Patients Should Know About Post-Operative Radiotherapy. Journal of Cancer Education, 2013, 28, 509-515.	1.3	3
15	Custirsen (OGX-011): Clusterin Inhibitor in Metastatic Prostate Cancer. Current Oncology Reports, 2013, 15, 113-118.	4.0	13
16	Evidence supporting the association of polyomavirus BK genome with prostate cancer. Medical Microbiology and Immunology, 2013, 202, 425-430.	4.8	20
17	Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 5-10.	6.4	137
18	MRI-guided core biopsy of the prostate in the supine position – introduction of a simplified technique using large-bore magnet systems. European Radiology, 2013, 23, 1415-1419.	4.5	9

#	ARTICLE	IF	CITATIONS
19	The molecular basis for ethnic variation and histological subtype differences in prostate cancer. Science China Life Sciences, 2013, 56, 780-787.	4.9	7
20	The Relationship Between Nutrition and Prostate Cancer: Is More Always Better?. European Urology, 2013, 63, 810-820.	1.9	80
22	Complications and Quality of Life After Template-assisted Transperineal Prostate Biopsy in Patients Eligible for Focal Therapy. Urology, 2013, 81, 1291-1296.	1.0	36
23	Diabetes and prostate cancer—an open debate. Nature Reviews Urology, 2013, 10, 12-14.	3.8	11
24	Serum Isoform [ $\alpha^2$ ]proPSA Derivatives Significantly Improve Prediction of Prostate Cancer at Initial Biopsy in a Total PSA Range of 2–10 ng/ml: A Multicentric European Study. European Urology, 2013, 63, 986-994.	1.9	176
25	Prostate Cancer Screening: Biases and the Need for Consensus. Journal of the National Cancer Institute, 2013, 105, 1522-1524.	6.3	11
26	How Well Does the PCA3—incorporated Chun Nomogram Perform in Predicting Prostate Biopsy Outcome Among South African Men?. European Urology, 2013, 63, 1135-1136.	1.9	0
27	Cancer incidence and mortality in people aged less than 75 years: Changes in Australia over the period 1987–2007. Cancer Epidemiology, 2013, 37, 780-787.	1.9	20
28	Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer. Drugs, 2013, 73, 1723-1732.	10.9	32
29	The value and limitations of contrast-enhanced transrectal ultrasonography for the detection of prostate cancer. European Journal of Radiology, 2013, 82, e641-e647.	2.6	36
30	The fat side of prostate cancer. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2013, 1831, 1518-1532.	2.4	228
31	Micronutrient intake and risk of prostate cancer in a cohort of middle-aged, Danish men. Cancer Causes and Control, 2013, 24, 1129-1135.	1.8	30
32	Robot-assisted radical prostatectomy: a case series of the first 100 patients -constitutional introduction and implementation on the basis of comprehensive department of minimal invasive surgery center-. BMC Research Notes, 2013, 6, 436.	1.4	11
33	Evolution of advanced technologies in prostate cancer radiotherapy. Nature Reviews Urology, 2013, 10, 565-579.	3.8	61
34	Prostate-specific antigen (PSA) rate of decline post external beam radiotherapy predicts prostate cancer death. Radiotherapy and Oncology, 2013, 107, 129-133.	0.6	18
35	Management of Biochemical Recurrence After Primary Treatment of Prostate Cancer: A Systematic Review of the Literature. European Urology, 2013, 64, 905-915.	1.9	128
36	Magnetic Resonance Imaging—Targeted Prostate Biopsy: Back to the Future. European Urology, 2013, 63, 141-142.	1.9	11
37	Anti-proliferative effects of physiological concentrations of enterolactone in models of prostate tumourigenesis. Molecular Nutrition and Food Research, 2013, 57, 212-224.	3.3	17

#	ARTICLE	IF	CITATIONS
38	Management of prostate cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. <i>Lancet Oncology</i> , The, 2013, 14, e524-e534.	10.7	42
39	Application of 99mTechnetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) SPECT/CT in prostate cancer patients. <i>Nuclear Medicine and Biology</i> , 2013, 40, 933-938.	0.6	20
40	The Burden of Urinary Incontinence and Urinary Bother Among Elderly Prostate Cancer Survivors. <i>European Urology</i> , 2013, 64, 672-679.	1.9	28
41	Metformin and Prostate Cancer: Reduced Development of Castration-resistant Disease and Prostate Cancer Mortality. <i>European Urology</i> , 2013, 63, 709-716.	1.9	152
42	Genetic polymorphisms of xeroderma pigmentosum group D gene Asp312Asn and Lys751Gln and susceptibility to prostate cancer: A systematic review and meta-analysis. <i>Gene</i> , 2013, 530, 309-314.	2.2	12
43	Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort. <i>European Journal of Cancer</i> , 2013, 49, 3041-3048.	2.8	12
44	Manipulating the epigenome for the treatment of urological malignancies. , 2013, 138, 185-196.		17
45	Selecting the Optimal Candidate for Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. <i>European Urology</i> , 2013, 63, 998-1008.	1.9	107
46	Morbidity After Transperineal Prostate Biopsy in 3000 Patients Undergoing 12 vs 18 vs More Than 24 Needle Cores. <i>Urology</i> , 2013, 81, 1142-1146.	1.0	120
47	Early results of prostate cancer radiation therapy: an analysis with emphasis on research strategies to improve treatment delivery and outcomes. <i>BMC Cancer</i> , 2013, 13, 23.	2.6	22
48	CYP1A1 MspI polymorphism is associated with prostate cancer susceptibility: evidence from a meta-analysis. <i>Molecular Biology Reports</i> , 2013, 40, 3483-3491.	2.3	24
49	Artificial neural networks and prostate cancer—tools for diagnosis and management. <i>Nature Reviews Urology</i> , 2013, 10, 174-182.	3.8	63
50	HDAC6 Regulation of Androgen Signaling in Prostate Cancer. , 2013, , 443-459.		1
51	Obesity and Prostate Cancer: Weighing the Evidence. <i>European Urology</i> , 2013, 63, 800-809.	1.9	458
52	Validation of a Genomic Classifier that Predicts Metastasis Following Radical Prostatectomy in an At Risk Patient Population. <i>Journal of Urology</i> , 2013, 190, 2047-2053.	0.4	280
53	Model-based patterns in prostate cancer mortality worldwide. <i>British Journal of Cancer</i> , 2013, 108, 2354-2366.	6.4	18
54	Predictors of Health-related Quality of Life and Adjustment to Prostate Cancer During Active Surveillance. <i>European Urology</i> , 2013, 64, 30-36.	1.9	81
55	Epidemiology of prostate cancer in the Asia-Pacific region. <i>Prostate International</i> , 2013, 1, 47-58.	2.3	146

#	ARTICLE	IF	CITATIONS
56	Beyond the Limits of Oxygen: Effects of Hypoxia in a Hormone-Independent Prostate Cancer Cell Line. <i>ISRN Oncology</i> , 2013, 2013, 1-8.	2.1	10
57	Pomegranate Extracts in the Management of Men's Urologic Health: Scientific Rationale and Preclinical and Clinical Data. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-9.	1.2	4
58	Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer. <i>Prostate Cancer</i> , 2013, 2013, 1-23.	0.6	48
59	Prostate cancer in Denmark 1978â€“2009 â€” trends in incidence and mortality. <i>Acta OncolÃ³gica</i> , 2013, 52, 831-836.	1.8	36
60	Factors influencing primary care physiciansâ€™ decision to order prostate-specific antigen (PSA) test for men without prostate cancer. <i>Acta OncolÃ³gica</i> , 2013, 52, 1602-1608.	1.8	19
61	The epidemiology of high-risk prostate cancer. <i>Current Opinion in Urology</i> , 2013, 23, 331-336.	1.8	48
62	Should Bone Scan be Performed in Chinese Prostate Cancer Patients at the Time of Diagnosis?. <i>Urologia Internationalis</i> , 2013, 91, 160-164.	1.3	10
63	TMPRSS2-ERG Fusion Transcripts in Matched Urine and Needle Rinse Material after Biopsy for the Detection of Prostate Cancer. <i>Clinical Chemistry</i> , 2013, 59, 245-251.	3.2	10
64	Dietary Fat and Reduced Prostate Cancer Mortality. <i>JAMA Internal Medicine</i> , 2013, 173, 1326.	5.1	1
65	Association Between Metformin Use and Risk of Prostate Cancer and Its Grade. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1123-1131.	6.3	76
66	TÃ¼rk Toplumunda GSTM1, GSTP1 ve GSTT1 Gen Polimorfizmlerinin Prostat Kanseri Riski Ãœzerine Etkileri. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2013, 23, 242-249.	0.1	1
67	Endothelial nitric oxide synthase gene polymorphisms and prostate cancer risk in <sc>S</sc>erbian population. <i>International Journal of Experimental Pathology</i> , 2013, 94, 355-361.	1.3	22
68	Ejaculation Profiles of Men Following Radiation Therapy for Prostate Cancer. <i>Journal of Sexual Medicine</i> , 2013, 10, 1410-1416.	0.6	35
69	Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. <i>Prostate Cancer and Prostatic Diseases</i> , 2013, 16, 391-397.	3.9	53
70	MIRNA-296-3p-ICAM-1 axis promotes metastasis of prostate cancer by possible enhancing survival of natural killer cell-resistant circulating tumour cells. <i>Cell Death and Disease</i> , 2013, 4, e928-e928.	6.3	95
71	TMPRSS2-ERG Fusion Transcripts in Matched Urine and Needle Rinse Material after Biopsy for the Detection of Prostate Cancer: Really a Step Forward?. <i>Clinical Chemistry</i> , 2013, 59, 9-10.	3.2	0
72	Prevalence of Prostate Cancer on Autopsy: Cross-Sectional Study on Unscreened Caucasian and Asian Men. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1050-1058.	6.3	208
73	Is Prostate-Specific Antigen Effective for Population Screening of Prostate Cancer? A Systematic Review. <i>Annals of Laboratory Medicine</i> , 2013, 33, 233-241.	2.5	21

#	ARTICLE	IF	CITATIONS
74	Serum levels of Sex Hormone Binding Globulin (SHBG) are not predictive of prostate cancer diagnosis and aggressiveness: results from an Italian biopsy cohort. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2013, 39, 793-799.	1.5	8
75	Overall- and Disease-Specific Survival in Prostate Cancer: Too Long to Wait?. <i>Medical Radiology</i> , 2013, , 65-73.	0.1	1
76	The Role of Physiotherapy in the Pre and Post Treatment Interventions in Prostate Cancer Patients. , 2013, , .		0
77	Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer. <i>Oncotarget</i> , 2014, 5, 11091-11102.	1.8	160
78	Mobile Application-Based Seoul National University Prostate Cancer Risk Calculator: Development, Validation, and Comparative Analysis with Two Western Risk Calculators in Korean Men. <i>PLoS ONE</i> , 2014, 9, e94441.	2.5	15
79	Pre- and Post-Operative Nomograms to Predict Recurrence-Free Probability in Korean Men with Clinically Localized Prostate Cancer. <i>PLoS ONE</i> , 2014, 9, e100053.	2.5	14
80	Copy Number Variation of GSTT1 and GSTM1 and the Risk of Prostate Cancer in a Caribbean Population of African Descent. <i>PLoS ONE</i> , 2014, 9, e107275.	2.5	19
81	The Anti-Proliferative Effects of Enterolactone in Prostate Cancer Cells: Evidence for the Role of DNA Licensing Genes, mi-R106b Cluster Expression, and PTEN Dosage. <i>Nutrients</i> , 2014, 6, 4839-4855.	4.1	25
82	A review of continuous vs intermittent androgen deprivation therapy: Redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a perpetual dispute. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2014, 40, 3-15.	1.5	12
83	Management of end-stage erectile dysfunction and stress urinary incontinence after radical prostatectomy by simultaneous dual implantation using a single trans-scrotal incision: surgical technique and outcomes. <i>Asian Journal of Andrology</i> , 2015, 17, 792.	1.6	14
84	Prostate cancer trends in Latvia during 1990–2012: Incidence, prevalence, mortality, and survival rates. <i>Medicina (Lithuania)</i> , 2014, 50, 313-317.	2.0	4
85	Hematologic changes during prostate cancer radiation therapy are dependent on the treatment volume. <i>Future Oncology</i> , 2014, 10, 835-843.	2.4	22
86	Down-regulation of Dicer and Ago2 is associated with cell proliferation and apoptosis in prostate cancer. <i>Tumor Biology</i> , 2014, 35, 11571-11578.	1.8	32
87	Sustained Exposure to the Investigational Kisspeptin Analog, TAK-448, Down-Regulates Testosterone into the Castration Range in Healthy Males and in Patients With Prostate Cancer: Results From Two Phase 1 Studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1445-E1453.	3.6	49
88	Left lobe of the prostate during clinical prostate cancer screening: the dark side of the gland for right-handed examiners. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 157-162.	3.9	0
89	PSMA, EpCAM, VEGF and GRPR as Imaging Targets in Locally Recurrent Prostate Cancer after Radiotherapy. <i>International Journal of Molecular Sciences</i> , 2014, 15, 6046-6061.	4.1	54
90	Mechanisms Linking Excess Adiposity and Carcinogenesis Promotion. <i>Frontiers in Endocrinology</i> , 2014, 5, 65.	3.5	110
91	The Host Microenvironment Influences Prostate Cancer Invasion, Systemic Spread, Bone Colonization, and Osteoblastic Metastasis. <i>Frontiers in Oncology</i> , 2014, 4, 364.	2.8	50

#	ARTICLE	IF	CITATIONS
92	Imaging and Markers as Novel Diagnostic Tools in Detecting Insignificant Prostate Cancer: A Critical Overview. International Scholarly Research Notices, 2014, 2014, 1-16.	0.9	0
93	Intensified Adjuvant Treatment of Prostate Carcinoma: Feasibility Analysis of a Phase I/II Trial. BioMed Research International, 2014, 2014, 1-8.	1.9	2
94	Noncoding RNAs as Novel Biomarkers in Prostate Cancer. BioMed Research International, 2014, 2014, 1-17.	1.9	83
95	Protocol for the ProCare Trial: a phase II randomised controlled trial of shared care for follow-up of men with prostate cancer. BMJ Open, 2014, 4, e004972.	1.9	15
96	An Intelligent Serious Game for Supporting African and African Caribbean Men during Pre- and Post-Diagnosis of Prostate Cancer. , 2014, , .		0
97	Beyond abiraterone. Cancer Biology and Therapy, 2014, 15, 149-155.	3.4	8
98	Advanced prostate cancer: advancing patient care. Trends in Urology & Men's Health, 2014, 5, 40-42.	0.4	0
99	Modernizing the Diagnostic and Decision-Making Pathway for Prostate Cancer. Clinical Cancer Research, 2014, 20, 6254-6257.	7.0	17
101	Focal cryoablation: a treatment option for unilateral low-risk prostate cancer. BJU International, 2014, 113, 56-64.	2.5	69
102	Differences in prostate cancer grade, stage, and location in radical prostatectomy specimens from United States and Japan. Prostate, 2014, 74, 321-325.	2.3	27
103	Down-modulation of Bcl-2 sensitizes PTEN-mutated prostate cancer cells to starvation and taxanes. Prostate, 2014, 74, 1411-1422.	2.3	14
104	Positive Surgical Margin Trends In Patients With Pathologic T3 Prostate Cancer Treated With Robot Assisted Radical Prostatectomy. Journal of Endourology, 0, , 150127063130004.	2.1	1
105	Increased association of the ERG oncoprotein expression in advanced stages of prostate cancer in Filipinos. Prostate, 2014, 74, 1079-1085.	2.3	7
106	Survival after radical prostatectomy for clinically localised prostate cancer: a population-based study. BJU International, 2014, 113, 541-547.	2.5	18
107	The validity of the distress thermometer in prostate cancer populations. Psycho-Oncology, 2014, 23, 195-203.	2.3	104
108	Non-coding RNAs as biomarkers for metastatic prostate cancer. Lancet Oncology, The, 2014, 15, 1412-1413.	10.7	7
109	Corpulence is the crucial factor: Association of testosterone and/or obesity with prostate cancer stage. International Journal of Urology, 2014, 21, 980-986.	1.0	11
110	Survival, Continence and Potency (SCP) recovery after radical retropubic prostatectomy: A long-term combined evaluation of surgical outcomes. European Journal of Surgical Oncology, 2014, 40, 1716-1723.	1.0	19

#	ARTICLE	IF	CITATIONS
111	The feature of metabolic syndrome is a risk factor for biochemical recurrence after radical prostatectomy. <i>Journal of Surgical Oncology</i> , 2014, 110, 476-481.	1.7	36
112	Prostate-specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancer. <i>BJU International</i> , 2014, 113, E98-105.	2.5	11
113	Prostasomes: extracellular vesicles from the prostate. <i>Reproduction</i> , 2014, 147, R1-R14.	2.6	155
114	Men's knowledge and attitudes towards dietary prevention of a prostate cancer diagnosis: a qualitative study. <i>BMC Cancer</i> , 2014, 14, 812.	2.6	15
115	Prostate Cancer, Prostate Cancer Death, and Death from Other Causes, Among Men with Metabolic Aberrations. <i>Epidemiology</i> , 2014, 25, 823-828.	2.7	25
116	Living with untreated prostate cancer. <i>Current Opinion in Urology</i> , 2014, 24, 311-317.	1.8	10
117	Phosphorus Magnetic Resonance Spectroscopic Imaging at 7 T in Patients With Prostate Cancer. <i>Investigative Radiology</i> , 2014, 49, 363-372.	6.2	20
118	Prostate cancer in Asian men. <i>Nature Reviews Urology</i> , 2014, 11, 197-212.	3.8	230
119	Recommendations on screening for prostate cancer with the prostate-specific antigen test. <i>Cmaj</i> , 2014, 186, 1225-1234.	2.0	170
120	Prostate cancer in Asia: A collaborative report. <i>Asian Journal of Urology</i> , 2014, 1, 15-29.	1.2	136
121	Prostate Cancer in South Africa: Pathology Based National Cancer Registry Data (1986-2006) and Mortality Rates (1997-2009). <i>Prostate Cancer</i> , 2014, 2014, 1-9.	0.6	28
122	Febrile Urinary Tract Infection After Prostate Biopsy and Quinolone Resistance. <i>Korean Journal of Urology</i> , 2014, 55, 660.	1.2	11
123	Clinicopathologic Differences Between Prostate Cancers Detected During Initial and Repeat Transrectal Ultrasound-Guided Biopsy in Korea. <i>Korean Journal of Urology</i> , 2014, 55, 718.	1.2	3
124	Detection Rate of Anterior Prostate Cancer in 226 Patients Submitted to Initial and Repeat Transperineal Biopsy. <i>Urologia Internationalis</i> , 2014, 93, 189-192.	1.3	18
125	Influence of Lifestyle Factors on Breast Cancer Risk. <i>Breast Care</i> , 2014, 9, 407-414.	1.4	51
126	An incidence model of the cost of advanced prostate cancer in Spain. <i>Journal of Medical Economics</i> , 2014, 17, 125-131.	2.1	7
127	Predicting the risk of bone metastasis in prostate cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 3-11.	7.7	53
128	Revised Gleason Grading System Is a Better Predictor of Indolent Prostate Cancer at the Time of Diagnosis: Retrospective Clinical-Pathological Study on Matched Biopsy and Radical Prostatectomy Specimens. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 325-329.	1.9	4



#	ARTICLE	IF	CITATIONS
129	Is There a Role for Body Mass Index in the Assessment of Prostate Cancer Risk on Biopsy?. Journal of Urology, 2014, 192, 1094-1099.	0.4	18
130	Serum levels of 17- $\beta$ -estradiol are not predictive of prostate cancer diagnosis and aggressiveness: Results from an Italian biopsy cohort. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 35.e9-35.e13.	1.6	2
131	Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment. European Urology, 2014, 65, 289-299.	1.9	113
133	Development and validation of nomograms to predict the recovery of urinary continence after radical prostatectomy: comparisons between immediate, early, and late continence. World Journal of Urology, 2014, 32, 437-444.	2.2	33
134	Impact of international variation of prostate cancer on a predictive nomogram for biochemical recurrence in clinically localised prostate cancer. World Journal of Urology, 2014, 32, 399-405.	2.2	12
135	Prostate biopsy: results and advantages of the transperineal approach—twenty-year experience of a single center. World Journal of Urology, 2014, 32, 373-377.	2.2	34
136	Time trends of cancer incidence and mortality in Catalonia during 1993–2007. Clinical and Translational Oncology, 2014, 16, 18-28.	2.4	37
137	MALDI mass spectrometry in prostate cancer biomarker discovery. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 940-949.	2.3	32
138	Planning for the future: cancer incidence projections in Switzerland up to 2019. BMC Public Health, 2014, 14, 102.	2.9	24
139	Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel. Cancer and Metastasis Reviews, 2014, 33, 657-671.	5.9	49
140	A genome-wide association study of prostate cancer in West African men. Human Genetics, 2014, 133, 509-521.	3.8	72
141	Evaluation of the TMPRSS2:ERG fusion for the detection of prostate cancer: a systematic review and meta-analysis. Tumor Biology, 2014, 35, 2157-2166.	1.8	11
142	Role of magnetic resonance imaging in defining a biopsy strategy for detection of prostate cancer. International Journal of Urology, 2014, 21, 5-11.	1.0	11
143	The Value of Magnetic Resonance Imaging in the Detection of Prostate Cancer in Patients with Previous Negative Biopsies and Elevated Prostate-specific Antigen Levels. Academic Radiology, 2014, 21, 578-589.	2.5	22
144	Prospective Study of Diagnostic Accuracy Comparing Prostate Cancer Detection by Transrectal Ultrasound—Guided Biopsy Versus Magnetic Resonance (MR) Imaging with Subsequent MR-guided Biopsy in Men Without Previous Prostate Biopsies. European Urology, 2014, 66, 22-29.	1.9	445
145	Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the <sc>S</sc>hared <sc>E</sc>qual <sc>A</sc>ccess <sc>R</sc>egional <sc>C</sc>ancer <sc>H</sc>ospital (<sc>SEARCH</sc>) database. BJU International, 2014, 114, 661-666.	2.5	46
146	Influence of peripheral whole-blood microRNA-7 and microRNA-221 high expression levels on the acquisition of castration-resistant prostate cancer: evidences from in vitro and in vivo studies. Tumor Biology, 2014, 35, 7105-7113.	1.8	34
147	Restoring TGF $\beta$ 1 pathway-related microRNAs: possible impact in metastatic prostate cancer development. Tumor Biology, 2014, 35, 6245-6253.	1.8	26

#	ARTICLE	IF	CITATIONS
148	Quinone propionic acidâ€‘based redoxâ€‘triggered polymer nanoparticles for drug delivery: Computational analysis and <i>in vitro</i> evaluation. Journal of Applied Polymer Science, 2014, 131, .	2.6	7
149	Phytoestrogens selective for the estrogen receptor beta exert anti-androgenic effects in castration resistant prostate cancer. Journal of Steroid Biochemistry and Molecular Biology, 2014, 139, 290-293.	2.5	29
150	Statins: protectors or pretenders in prostate cancer?. Trends in Endocrinology and Metabolism, 2014, 25, 188-196.	7.1	36
151	Assessment of Association between Common Variants at 17q12 and Prostate Cancer Riskâ€‘Evidence from Serbian Population and Metaâ€‘Analysis. Clinical and Translational Science, 2014, 7, 307-313.	3.1	5
152	PadÃ© optimization of noise-corrupted magnetic resonance spectroscopic time signals from fibroadenoma of the breast. Journal of Mathematical Chemistry, 2014, 52, 2680-2713.	1.5	14
153	Preclinical activity of multiple-target gold(III)-dithiocarbamate peptidomimetics in prostate cancer cells and xenografts. Future Medicinal Chemistry, 2014, 6, 1249-1263.	2.3	15
154	A Systematic Review and Meta-analysis of Tobacco Use and Prostate Cancer Mortality and Incidence in Prospective Cohort Studies. European Urology, 2014, 66, 1054-1064.	1.9	156
155	Increased nuclear factor erythroid 2â€‘related factor 2 expression predicts worse prognosis of prostate cancer patients treated with radical prostatectomy. Human Pathology, 2014, 45, 2211-2217.	2.0	4
156	Diffusion kurtosis imaging study of prostate cancer: Preliminary findings. Journal of Magnetic Resonance Imaging, 2014, 40, 723-729.	3.4	93
157	Obesity Increases the Risk for High-Grade Prostate Cancer: Results from the REDUCE Study. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2936-2942.	2.5	84
158	Epidemiology of prostate cancer in India. Meta Gene, 2014, 2, 596-605.	0.6	140
159	Enzalutamide: looking back at its preclinical discovery. Expert Opinion on Drug Discovery, 2014, 9, 837-845.	5.0	10
161	A DNA hypermethylation profile reveals new potential biomarkers for prostate cancer diagnosis and prognosis. Prostate, 2014, 74, 1171-1182.	2.3	58
162	Disease-specific outcomes of Radical Prostatectomies in Northern Norway; a case for the impact of perineural infiltration and postoperative PSA-doubling time. BMC Urology, 2014, 14, 49.	1.4	28
163	Prevention and early detection of prostate cancer. Lancet Oncology, The, 2014, 15, e484-e492.	10.7	372
164	Intensity-Modulated Radiation Therapy for Clinically Localized Prostate Cancer. Medical Radiology, 2014, , 95-102.	0.1	0
165	Serum levels of chromogranin A are not predictive of high-grade, poorly differentiated prostate cancer: Results from an Italian biopsy cohort. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 80-84.	1.6	11
166	A single centre experience of active surveillance as management strategy for low-risk prostate cancer in Ireland. Irish Journal of Medical Science, 2014, 183, 377-382.	1.5	13

#	ARTICLE	IF	CITATIONS
167	Enhanced expression of IMPDH2 promotes metastasis and advanced tumor progression in patients with prostate cancer. <i>Clinical and Translational Oncology</i> , 2014, 16, 906-913.	2.4	28
168	Negative Regulation of the Androgen Receptor Gene Through a Primate-Specific Androgen Response Element Present in the 5' UTR. <i>Hormones and Cancer</i> , 2014, 5, 299-311.	4.9	11
169	Diagnostic value of urine prostate cancer antigen 3 test using a cutoff value of 35 µg/L in patients with prostate cancer. <i>Tumor Biology</i> , 2014, 35, 8573-8580.	1.8	17
170	Reduced expression of PinX1 correlates to progressive features in patients with prostate cancer. <i>Cancer Cell International</i> , 2014, 14, 46.	4.1	25
171	Genetic variation: effect on prostate cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 446-456.	7.4	15
172	Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer. <i>Actas Urológicas Españolas (English Edition)</i> , 2014, 38, 327-333.	0.2	0
173	Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy. <i>European Urology</i> , 2014, 66, 32-39.	1.9	139
174	Sedentarism and overweight as risk factors for the detection of prostate cancer and its aggressiveness. <i>Actas Urológicas Españolas (English Edition)</i> , 2014, 38, 232-237.	0.2	11
175	MP74-15 THE EFFECT OF EJACULATION FREQUENCY ON SERUM PROSTATE SPECIFIC ANTIGEN LEVEL. <i>Journal of Urology</i> , 2014, 191, .	0.4	0
176	Second Primary Cancers Occurring after I-125 Brachytherapy as Monotherapy for Early Prostate Cancer. <i>Clinical Oncology</i> , 2014, 26, 210-215.	1.4	17
177	Expression of prostate stem cell antigen (PSCA) in prostate cancer: A tissue microarray study of Iranian patients. <i>Pathology Research and Practice</i> , 2014, 210, 18-23.	2.3	24
178	A Multinational, Multi-institutional Study Comparing Positive Surgical Margin Rates Among 22 393 Open, Laparoscopic, and Robot-assisted Radical Prostatectomy Patients. <i>European Urology</i> , 2014, 66, 450-456.	1.9	116
179	Age and Baseline Quality of Life at Radical Prostatectomy—Who Has the Most to Lose?. <i>Journal of Urology</i> , 2014, 192, 396-401.	0.4	24
180	Acetato de abiraterona prequimioterapia. Propuesta de un algoritmo de tratamiento en el carcinoma de próstata resistente a castración. <i>Actas Urológicas Españolas</i> , 2014, 38, 327-333.	0.7	3
181	Detectable Prostate-Specific Antigen Nadir During Androgen-Deprivation Therapy Predicts Adverse Prostate Cancer-Specific Outcomes: Results from the SEARCH Database. <i>European Urology</i> , 2014, 65, 620-627.	1.9	23
183	Sedentarismo y sobrepeso como factores de riesgo en la detección del cáncer de próstata y su agresividad. <i>Actas Urológicas Españolas</i> , 2014, 38, 232-237.	0.7	16
184	The Role of Robot-assisted Radical Prostatectomy and Pelvic Lymph Node Dissection in the Management of High-risk Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2014, 65, 918-927.	1.9	127
185	Cholesterol-induced activation of TRPM7 regulates cell proliferation, migration, and viability of human prostate cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2014, 1843, 1839-1850.	4.1	74

#	ARTICLE	IF	CITATIONS
186	Prostate-specific antigen and other serum and urine markers in prostate cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 99-112.	7.4	54
187	Noncoding RNAs in Prostate Cancer: The Long and the Short of It. <i>Clinical Cancer Research</i> , 2014, 20, 35-43.	7.0	59
188	Prospective Evaluation of Magnetic Resonance Imaging Guided In-bore Prostate Biopsy versus Systematic Transrectal Ultrasound Guided Prostate Biopsy in Biopsy Naïve Men with Elevated Prostate Specific Antigen. <i>Journal of Urology</i> , 2014, 192, 1374-1379.	0.4	98
189	Editorial Comment. <i>Journal of Urology</i> , 2014, 192, 736-736.	0.4	0
190	High-resolution NMR spectroscopy of human body fluids and tissues in relation to prostate cancer. <i>NMR in Biomedicine</i> , 2014, 27, 80-89.	2.8	47
193	Predictive factors of unfavorable prostate cancer in patients who underwent prostatectomy but eligible for active surveillance. <i>Prostate International</i> , 2014, 2, 70-75.	2.3	6
194	Surgery or radiotherapy for prostate cancer?. <i>BMJ, The</i> , 2014, 348, g1580-g1580.	6.0	2
197	Known Knowns, Known Unknowns, and Unknown Unknowns of High-intensity Focused Ultrasound for Prostate Cancer. <i>European Urology Focus</i> , 2015, 1, 171-172.	3.1	0
198	Impact of Early Diagnosis of Prostate Cancer on Survival Outcomes. <i>European Urology Focus</i> , 2015, 1, 137-146.	3.1	18
199	Trends in major cancer mortality in Korea, 1983-2012, with a joinpoint analysis. <i>Cancer Epidemiology</i> , 2015, 39, 939-946.	1.9	35
200	Prediction of biochemical recurrence after robot-assisted radical prostatectomy: Analysis of 784 Japanese patients. <i>International Journal of Urology</i> , 2015, 22, 188-193.	1.0	21
201	Assessing the effectiveness of decision aids for decision making in prostate cancer testing: a systematic review. <i>Psycho-Oncology</i> , 2015, 24, 1303-1315.	2.3	30
202	Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study. <i>BJU International</i> , 2015, 115, 736-743.	2.5	35
203	The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian Prostate Cancer Registry. <i>BJU International</i> , 2015, 115, 50-56.	2.5	80
204	Enhanced central memory cluster of differentiation 8+ and tumor antigen-specific T cells in prostate cancer patients receiving repeated in situ adenovirus-mediated suicide gene therapy. <i>Molecular and Clinical Oncology</i> , 2015, 3, 515-521.	1.0	7
205	Biomechanical modeling constrained surface-based image registration for prostate MR guided TRUS biopsy. <i>Medical Physics</i> , 2015, 42, 2470-2481.	3.0	18
206	Co-design of a Prostate Cancer Serious Game for African Caribbean Men. , 2015, , .		3
208	Comparison of pathological data between prostate biopsy and radical prostatectomy specimen in patients with low to very low risk prostate cancer. <i>Actas Urológicas Españolas (English Edition)</i> , 2015, 39, 482-487.	0.2	8

#	ARTICLE	IF	CITATIONS
209	Serum adiponectin concentration in 2,939 Japanese men undergoing screening for prostate cancer. <i>Prostate International</i> , 2015, 3, 87-92.	2.3	9
210	The dog prostate cancer (DPC-1) model: a reliable tool for molecular imaging of prostate tumors and metastases. <i>EJNMMI Research</i> , 2015, 5, 77.	2.5	6
211	Recepteur d'origine nantais (RON), more than a kinase: Role in castrate-resistant prostate cancer. <i>Molecular Carcinogenesis</i> , 2015, 54, 937-946.	2.7	6
212	Trends of prostate cancer incidence and mortality in Shanghai, China from 1973 to 2009. <i>Prostate</i> , 2015, 75, 1662-1668.	2.3	44
213	Adipocyte-derived monocyte chemotactic protein-1 (MCP-1) promotes prostate cancer progression through the induction of MMP-2 activity. <i>Prostate</i> , 2015, 75, 1009-1019.	2.3	45
214	Latent prostate cancer in Japanese men who die unnatural deaths: A forensic autopsy study. <i>Prostate</i> , 2015, 75, 917-922.	2.3	11
215	Preoperative erectile function and the pathologic features of prostate cancer. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2015, 41, 265-273.	1.5	2
216	Comparison of Pathological and Biochemical Outcomes after Radical Prostatectomy in Korean Patients with Serum PSA Ranges. <i>Journal of Korean Medical Science</i> , 2015, 30, 317.	2.5	3
217	Incidence of kidney, bladder, and prostate cancers in Korea: An update. <i>Korean Journal of Urology</i> , 2015, 56, 422.	1.2	35
218	Anterior prostate biopsy at initial and repeat evaluation: is it useful to detect significant prostate cancer?. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2015, 41, 844-848.	1.5	7
219	An epidemiological analysis of potential associations between C-reactive protein, inflammation, and prostate cancer in the male US population using the 2009-2010 National Health and Nutrition Examination Survey (NHANES) data. <i>Frontiers in Chemistry</i> , 2015, 3, 55.	3.6	10
220	Development of a Single Vial Kit Solution for Radiolabeling of 68Ga-DKFZ-PSMA-11 and Its Performance in Prostate Cancer Patients. <i>Molecules</i> , 2015, 20, 14860-14878.	3.8	48
221	Selenium and Chronic Diseases: A Nutritional Genomics Perspective. <i>Nutrients</i> , 2015, 7, 3621-3651.	4.1	73
222	Diagnostic Value of SFRP1 as a Favorable Predictive and Prognostic Biomarker in Patients with Prostate Cancer. <i>PLoS ONE</i> , 2015, 10, e0118276.	2.5	39
223	Trends and Outcome from Radical Therapy for Primary Non-Metastatic Prostate Cancer in a UK Population. <i>PLoS ONE</i> , 2015, 10, e0119494.	2.5	21
224	An Sp1 Modulated Regulatory Region Unique to Higher Primates Regulates Human Androgen Receptor Promoter Activity in Prostate Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0139990.	2.5	14
225	Repeat Targeted Prostate Biopsy under Guidance of Multiparametric MRI-Correlated Real-Time Contrast-Enhanced Ultrasound for Patients with Previous Negative Biopsy and Elevated Prostate-Specific Antigen: A Prospective Study. <i>PLoS ONE</i> , 2015, 10, e0130671.	2.5	2
226	Effect of gyromagnetic fields on human prostatic adenocarcinoma cells. <i>OncoTargets and Therapy</i> , 2015, 8, 3489.	2.0	4

#	ARTICLE	IF	CITATIONS
227	Doppler Ultrasound Measurement of Resistance Index in the Diagnosis of Prostate Cancer. Tumori, 2015, 101, 644-649.	1.1	2
228	Stability Assessment of Candidate Reference Genes in Urine Sediment of Prostate Cancer Patients for miRNA Applications. Disease Markers, 2015, 2015, 1-6.	1.3	30
229	Simultaneous Treatment with Statins and Aspirin Reduces the Risk of Prostate Cancer Detection and Tumorigenic Properties in Prostate Cancer Cell Lines. BioMed Research International, 2015, 2015, 1-11.	1.9	19
230	Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy. Oncotarget, 2015, 6, 14710-14719.	1.8	41
231	Targeting of cytosolic phospholipase A2 $\pm$ impedes cell cycle re-entry of quiescent prostate cancer cells. Oncotarget, 2015, 6, 34458-34474.	1.8	17
232	A Critical Analysis of the Learning Curve and Postlearning Curve Outcomes of Two Experience- and Volume-Matched Surgeons for Laparoscopic and Robot-Assisted Radical Prostatectomy. Journal of Endourology, 2015, 29, 939-947.	2.1	27
233	A core outcome set for localised prostate cancer effectiveness trials: protocol for a systematic review of the literature and stakeholder involvement through interviews and a Delphi survey. Trials, 2015, 16, 76.	1.6	46
234	Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Annals of Oncology, 2015, 26, 1660-1667.	1.2	45
235	Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial. Journal of Clinical Oncology, 2015, 33, 2151-2157.	1.6	39
236	Does imprint cytology improve the accuracy of transrectal prostate needle biopsy?. Diagnostic Cytopathology, 2015, 43, 91-97.	1.0	1
237	Serum 17 $\beta$ -estradiol fails as a marker in identification of aggressive tumour disease in patients with localized prostate cancer. World Journal of Urology, 2015, 33, 1979-1984.	2.2	2
238	Is it Safe to Omit Baseline Bone Scan for Newly Diagnosed Prostate Cancer Patients?. Urologia Internationalis, 2015, 94, 342-346.	1.3	7
239	Percent free prostate-specific antigen for prostate cancer diagnosis in Chinese men with a PSA of 4.0 $\pm$ 10.0 $\mu$ g/mL: Results from the Chinese Prostate Cancer Consortium. Asian Journal of Urology, 2015, 2, 107-113.	1.2	6
240	Cancer statistics for Hispanics/Latinos, 2015. Ca-A Cancer Journal for Clinicians, 2015, 65, 457-480.	329.8	397
241	Prostate cancer trends in Barbados: An analysis of the Barbados Urologic Diseases Survey database. Cancer Epidemiology, 2015, 39, 825-830.	1.9	3
242	Growth factors mediated cell signalling in prostate cancer progression: Implications in discovery of anti-prostate cancer agents. Chemico-Biological Interactions, 2015, 240, 120-133.	4.0	44
243	Review of Bioptic Gleason Scores by Central Pathologist Modifies the Risk Classification in Prostate Cancer. Urologia Internationalis, 2015, 95, 452-456.	1.3	8
244	Autophagy inhibition enhances silibinin-induced apoptosis by regulating reactive oxygen species production in human prostate cancer PC-3 cells. Biochemical and Biophysical Research Communications, 2015, 468, 151-156.	2.1	24



#	ARTICLE	IF	CITATIONS
245	Cost of illness of the prostate cancer in Japan—a time-trend analysis and future projections. BMC Health Services Research, 2015, 15, 453.	2.2	28
246	Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer. International Journal of Molecular Medicine, 2015, 35, 966-972.	4.0	38
247	Clinical and Microbiological Determinants of Infection After Transrectal Prostate Biopsy. Clinical Infectious Diseases, 2015, 60, 979-987.	5.8	49
248	International Variations and Trends in Renal Cell Carcinoma Incidence and Mortality. European Urology, 2015, 67, 519-530.	1.9	710
249	Prognostic Utility of PET in Prostate Cancer. PET Clinics, 2015, 10, 255-263.	3.0	5
250	A consensus on men's health status and policy in Asia: a Delphi survey. Public Health, 2015, 129, 60-67.	2.9	5
251	Functional significance of aberrantly expressed microRNAs in prostate cancer. International Journal of Urology, 2015, 22, 242-252.	1.0	89
252	Growth and migration of LNCaP prostate cancer cells are promoted by triclosan and benzophenone-1 via an androgen receptor signaling pathway. Environmental Toxicology and Pharmacology, 2015, 39, 568-576.	4.0	37
253	Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes. Prostate, 2015, 75, 280-291.	2.3	16
254	Prostate cancer: The main risk and protective factors—Epigenetic modifications. Annales D'Endocrinologie, 2015, 76, 25-41.	1.4	32
255	Genetic Variants within Endothelial Nitric Oxide Synthase Gene and Prostate Cancer: A Meta-Analysis. Clinical and Translational Science, 2015, 8, 23-31.	3.1	10
256	Global cancer statistics, 2012. Ca-A Cancer Journal for Clinicians, 2015, 65, 87-108.	329.8	23,881
257	Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?. Cancer, 2015, 121, 1414-1421.	4.1	12
258	TWIST overexpression predicts biochemical recurrence-free survival in prostate cancer patients treated with radical prostatectomy. Scandinavian Journal of Urology, 2015, 49, 51-57.	1.0	11
259	FOXO3a modulates WNT/ $\beta$ -catenin signaling and suppresses epithelial-to-mesenchymal transition in prostate cancer cells. Cellular Signalling, 2015, 27, 510-518.	3.6	132
260	MAPK and JAK/STAT pathways targeted by miR-23a and miR-23b in prostate cancer: computational and in vitro approaches. Tumor Biology, 2015, 36, 4203-4212.	1.8	46
261	Implication of high risk Human papillomavirus HR-HPV infection in prostate cancer in Indian population- A pioneering case-control analysis. Scientific Reports, 2015, 5, 7822.	3.3	39
262	Divergent effect of liver X receptor agonists on prostate-specific antigen expression is dependent on androgen receptor in prostate carcinoma cells. Prostate, 2015, 75, 603-615.	2.3	13

#	ARTICLE	IF	CITATIONS
263	The oncological outcome and validation of Japan Cancer of the Prostate Risk Assessment score among men treated with primary androgen-deprivation therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 495-503.	2.5	12
264	A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 373-380.	2.3	3
265	Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 274-283.	10.7	151
266	Opportunistic Testing Versus Organized Prostate-specific Antigen Screening: Outcome After 18 Years in the GÅrteborg Randomized Population-based Prostate Cancer Screening Trial. <i>European Urology</i> , 2015, 68, 354-360.	1.9	110
267	Is it necessary to perform week three dosimetric analysis in low-dose-rate brachytherapy for prostate cancer when day 0 dosimetry is done? A quality assurance assessment. <i>Brachytherapy</i> , 2015, 14, 316-321.	0.5	8
268	Comparative Effectiveness of Targeted vs Empirical Antibiotic Prophylaxis to Prevent Sepsis from Transrectal Prostate Biopsy: A Retrospective Analysis. <i>Journal of Urology</i> , 2015, 194, 397-402.	0.4	47
269	Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme. <i>European Journal of Cancer</i> , 2015, 51, 1630-1637.	2.8	23
270	Medium-term oncological outcomes for extended vs saturation biopsy and transrectal vs transperineal biopsy in active surveillance for prostate cancer. <i>BJU International</i> , 2015, 115, 884-891.	2.5	40
271	Associations of Plasma Concentrations of Dichlorodiphenyldichloroethylene and Polychlorinated Biphenyls with Prostate Cancer: A Case-Control Study in Guadeloupe (French West Indies). <i>Environmental Health Perspectives</i> , 2015, 123, 317-323.	6.0	43
272	Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?. <i>Current Urology Reports</i> , 2015, 16, 59.	2.2	15
273	A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels. <i>Psycho-Oncology</i> , 2015, 24, 348-354.	2.3	66
274	Plakophilin 1-deficient cells upregulate SPOCK1: implications for prostate cancer progression. <i>Tumor Biology</i> , 2015, 36, 9567-9577.	1.8	24
275	Radical Prostatectomy for Locally Advanced Prostate Cancer: Current Status. <i>Urology</i> , 2015, 86, 10-15.	1.0	21
276	A new optimization method using a compressed sensing inspired solver for real-time LDR-brachytherapy treatment planning. <i>Physics in Medicine and Biology</i> , 2015, 60, 2179-2194.	3.0	14
277	Multiparametric magnetic resonance imaging predicts the presence of prostate cancer in patients with negative prostate biopsy. <i>Actas Urológicas Españolas (English Edition)</i> , 2015, 39, 85-91.	0.2	4
278	Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2143-2150.	1.6	213
279	Comparación de datos anatomopatológicos entre biopsia de próstata y pieza de prostatectomía radical en pacientes con cáncer de bajo y muy bajo riesgo. <i>Actas Urológicas Españolas</i> , 2015, 39, 482-487.	0.7	9
280	Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study. <i>European Urology</i> , 2015, 68, 132-138.	1.9	67



#	ARTICLE	IF	CITATIONS
281	Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe. <i>European Urology</i> , 2015, 67, 904-912.	1.9	18
282	Quantitative urinary proteomics using stable isotope labelling by peptide dimethylation in patients with prostate cancer. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 3393-3404.	3.7	11
283	Guidance on Patient Consultation. Current Evidence for Prostate-Specific Antigen Screening in Healthy Men and Treatment Options for Men with Proven Localised Prostate Cancer. <i>Current Urology Reports</i> , 2015, 16, 28.	2.2	1
284	Expression of human kallikrein 1-related peptidase 4 (KLK4) and MET phosphorylation in prostate cancer tissue: immunohistochemical analysis. <i>Human Cell</i> , 2015, 28, 133-142.	2.7	19
285	Gleason Score at Diagnosis Predicts the Rate of Detection of <sup>18</sup> F-Choline PET/CT Performed When Biochemical Evidence Indicates Recurrence of Prostate Cancer: Experience with 1,000 Patients. <i>Journal of Nuclear Medicine</i> , 2015, 56, 209-215.	5.0	69
286	Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer cells. <i>BMC Cancer</i> , 2015, 15, 9.	2.6	41
287	3D vs 2D laparoscopic radical prostatectomy in organ-confined prostate cancer: comparison of operative data and pentapecta rates: a single cohort study. <i>BMC Urology</i> , 2015, 15, 12.	1.4	46
288	Nutrition, dietary interventions and prostate cancer: the latest evidence. <i>BMC Medicine</i> , 2015, 13, 3.	5.5	112
289	Prostate-specific antigen-based screening: controversy and guidelines. <i>BMC Medicine</i> , 2015, 13, 61.	5.5	84
290	Comportamiento de la testosterona total y libre en suero como predictores del riesgo de cáncer de próstata y de su agresividad. <i>Actas Urológicas Españolas</i> , 2015, 39, 573-581.	0.7	9
291	The Potential Harm of Prostate Cancer Health Supplements. <i>American Journal of Lifestyle Medicine</i> , 2015, 9, 457-458.	1.9	0
292	Identification and Diagnostic Performance of a Small RNA within the PCA3 and BMCC1 Gene Locus That Potentially Targets mRNA. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 268-275.	2.5	10
293	Effect of Metformin, Rapamycin, and Their Combination on Growth and Progression of Prostate Tumors in HiMyc Mice. <i>Cancer Prevention Research</i> , 2015, 8, 597-606.	1.5	36
294	Should abdominal sequences be included in prostate cancer MR staging studies?. <i>European Journal of Radiology</i> , 2015, 84, 1019-1022.	2.6	4
295	Replication and Heritability of Prostate Cancer Risk Variants: Impact of Population-Specific Factors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 938-943.	2.5	13
296	Is further screening of men with baseline PSA $\leq 1$ ng/mL worthwhile? The discussion continues-Results of the Swiss ERSPC (Aarau). <i>International Journal of Cancer</i> , 2015, 137, 553-559.	5.1	13
297	Altered Glycosylation in Prostate Cancer. <i>Advances in Cancer Research</i> , 2015, 126, 345-382.	5.0	91
298	Preprostate Biopsy Rectal Culture and Postbiopsy Sepsis. <i>Urologic Clinics of North America</i> , 2015, 42, 449-458.	1.8	7

[illegible]

#	ARTICLE	IF	CITATIONS
317	Coffee Consumption and Prostate Cancer. , 2015, , 359-366.		0
318	On the relationship between tumor structure and complexity of the spatial distribution of cancer cell nuclei: A fractal geometrical model of prostate carcinoma. Prostate, 2015, 75, 399-414.	2.3	28
319	Intratumour Heterogeneity in Urologic Cancers: From Molecular Evidence to Clinical Implications. European Urology, 2015, 67, 729-737.	1.9	100
320	Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification. European Urology, 2015, 67, 619-626.	1.9	129
321	Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer. Journal of Cancer Research and Clinical Oncology, 2015, 141, 759-765.	2.5	4
322	La resonancia magn�tica multiparam�trica predice la presencia de c�ncer de pr�stata en pacientes con biopsia prost�tica negativa. Actas Urol�gicas Espa�olas, 2015, 39, 85-91.	0.7	8
323	Matched comparison of robot�assisted, laparoscopic and open radical prostatectomy regarding pathologic and oncologic outcomes in obese patients. World Journal of Urology, 2015, 33, 397-402.	2.2	10
324	Prostate Cancer Prognostic Factors Among Asian Patients Born in the US Compared to Those Born Abroad. Journal of Immigrant and Minority Health, 2015, 17, 625-631.	1.6	6
325	Prostate cancer screening in Brazil: should it be done or not?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2016, 42, 1069-1080.	1.5	8
326	Oncolytic adenovirus-mediated therapy for prostate cancer. Oncolytic Virotherapy, 2016, Volume 5, 45-57.	6.0	10
327	Prostate Cancer Risk in Relation to CYP3A4 and CYP3A5 Genotypes in the Bangladeshi Population. Dhaka University Journal of Pharmaceutical Sciences, 2016, 14, 179-185.	0.2	1
328	Triiodothyronine Attenuates Prostate Cancer Progression Mediated by �2-Adrenergic Stimulation. Molecular Medicine, 2016, 22, 1-11.	4.4	24
329	Evolving Recommendations on Prostate Cancer Screening. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e80-e87.	3.8	8
330	Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer. Aging, 2016, 8, 2702-2712.	3.1	27
331	A Clinicopathological Profile of Prostate Cancer in Trinidad and Tobago. Advances in Urology, 2016, 2016, 1-5.	1.3	10
332	What Prevents Men Aged 40��64 Years from Prostate Cancer Screening in Namibia?. Journal of Cancer Epidemiology, 2016, 2016, 1-9.	1.1	17
333	Diet, Lifestyles, Family History, and Prostate Cancer Incidence in an East Algerian Patient Group. BioMed Research International, 2016, 2016, 1-9.	1.9	11
334	Danish Prostate Cancer Registry &ndash; methodology and early results from a novel national database. Clinical Epidemiology, 2016, Volume 8, 351-360.	3.0	25

#	ARTICLE	IF	CITATIONS
335	Information and communication technology and climate change adaptation: Evidence from selected mining companies in South Africa. <i>Jamba: Journal of Disaster Risk Studies</i> , 2016, 8, 250.	0.9	12
336	An Estimate of the Incidence of Prostate Cancer in Africa: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0153496.	2.5	121
337	Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study. <i>PLoS Medicine</i> , 2016, 13, e1002063.	8.4	51
338	Polymorphisms of Estrogen Metabolism-Related Genes and Prostate Cancer Risk in Two Populations of African Ancestry. <i>PLoS ONE</i> , 2016, 11, e0153609.	2.5	18
339	An assessment of GLOBOCAN methods for deriving national estimates of cancer incidence. <i>Bulletin of the World Health Organization</i> , 2016, 94, 174-184.	3.3	81
340	Couple-Based Psychosexual Support Following Prostate Cancer Surgery: Results of a Feasibility Pilot Randomized Control Trial. <i>Journal of Sexual Medicine</i> , 2016, 13, 1233-1242.	0.6	26
341	Glutathione Peroxidase 3 Inhibits Prostate Tumorigenesis in TRAMP Mice. <i>Prostate</i> , 2016, 76, 1387-1398.	2.3	24
342	Trends in prostate cancer incidence and mortality in Canada during the era of prostate-specific antigen screening. <i>CMAJ Open</i> , 2016, 4, E73-E79.	2.4	23
343	International long-term trends and recent patterns in the incidence of leukemias and lymphomas among children and adolescents ages 0-19 years. <i>International Journal of Cancer</i> , 2016, 138, 1862-1874.	5.1	70
344	Body mass index in relation to serum prostate-specific antigen levels and prostate cancer risk. <i>International Journal of Cancer</i> , 2016, 139, 50-57.	5.1	25
345	Canadian Nurses' Perspectives on Prostate Cancer Support Groups. <i>Cancer Nursing</i> , 2016, 39, 197-204.	1.5	2
346	Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study. <i>International Journal of Urology</i> , 2016, 23, 404-411.	1.0	26
347	Perinatal and childhood factors and risk of prostate cancer in adulthood: MCC-Spain case-control study. <i>Cancer Epidemiology</i> , 2016, 43, 49-55.	1.9	8
348	Cancer incidence predictions in the North of Portugal: keeping population-based cancer registration up to date. <i>European Journal of Cancer Prevention</i> , 2016, 25, 472-480.	1.3	10
349	Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 380-384.	3.9	40
350	Absorption, Distribution, and Excretion of the Investigational Agent Orteronel (TAK-700) in Healthy Male Subjects: A Phase 1, Open-Label, Single-Dose Study. <i>Clinical Pharmacology in Drug Development</i> , 2016, 5, 180-187.	1.6	1
351	A retrospective analysis of Victorian and South Australian clinical registries for prostate cancer: trends in clinical presentation and management of the disease. <i>BMC Cancer</i> , 2016, 16, 607.	2.6	21
352	HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method. <i>Oncology Letters</i> , 2016, 12, 4651-4658.	1.8	19

#	ARTICLE	IF	CITATIONS
353	Bax-interacting factor-1 inhibits cell proliferation and promotes apoptosis in prostate cancer cells. <i>Oncology Reports</i> , 2016, 36, 3513-3521.	2.6	9
354	Occupational exposure to solar ultraviolet radiation and the risk of prostate cancer. <i>Occupational and Environmental Medicine</i> , 2016, 73, oemed-2016-103567.	2.8	5
355	PROCEE: a PROstate Cancer Evaluation and Education serious game for African Caribbean men. <i>Journal of Assistive Technologies</i> , 2016, 10, 199-210.	0.8	4
356	Recurrent scrotal edema in a patient with radiation enteritis: A case report. <i>Molecular and Clinical Oncology</i> , 2016, 5, 79-82.	1.0	2
357	International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries. <i>ESMO Open</i> , 2016, 1, e000040.	4.5	34
358	A combinatorial Bayesian and Dirichlet model for prostate MR image segmentation using probabilistic image features. <i>Physics in Medicine and Biology</i> , 2016, 61, 6085-6104.	3.0	4
359	Incidence of intraductal carcinoma, multifocality and bilateral significant disease in radical prostatectomy specimens from Japan and United States. <i>Pathology International</i> , 2016, 66, 672-677.	1.3	5
360	Occupational risk factors for prostate cancer in an area of former coal, iron, and steel industries in Germany. Part 1: Results from a study performed in the 1980s. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2016, 79, 1125-1129.	2.3	2
362	Evidence for Masturbation and Prostate Cancer Risk: Do We Have a Verdict?. <i>Sexual Medicine Reviews</i> , 2016, 4, 229-234.	2.9	7
363	Comparison of $T_2$ mapping with diffusion-weighted imaging in the characterization of low-grade vs intermediate-grade and high-grade prostate cancer. <i>British Journal of Radiology</i> , 2016, 89, 20151076.	2.2	7
364	In touch with your feminine side: how oestrogen metabolism impacts prostate cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, R249-R266.	3.1	16
365	Is it appropriate to conduct conventional active surveillance for Asian men with low-risk prostate cancer?. <i>International Urology and Nephrology</i> , 2016, 48, 1287-1289.	1.4	2
366	Accurate prediction tools in prostate cancer require consistent assessment of included variables. <i>Scandinavian Journal of Urology</i> , 2016, 50, 260-266.	1.0	3
367	Systemic Radioligand Therapy with $^{177}\text{Lu}$ Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2016, 196, 382-391.	0.4	166
368	Epigenetic effects of prenatal estradiol- $17\beta$ exposure on the reproductive system of pigs. <i>Molecular and Cellular Endocrinology</i> , 2016, 430, 125-137.	3.2	11
369	Urologic cancer in Taiwan. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 605-609.	1.3	54
370	External Evaluation of a Novel Prostate Cancer Risk Calculator (ProstateCheck) Based on Data from the Swiss Arm of the ERSPC. <i>Journal of Urology</i> , 2016, 196, 1402-1407.	0.4	8
371	Cancer patterns in Karachi (all districts), Pakistan: First results (2010-2015) from a Pathology based cancer registry of the largest government-run diagnostic and reference center of Karachi. <i>Cancer Epidemiology</i> , 2016, 44, 114-122.	1.9	26

#	ARTICLE	IF	CITATIONS
372	Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer. <i>Cancer Immunology Research</i> , 2016, 4, 881-892.	3.4	57
373	Association of serum prostate-specific antigen levels with the results of the prostate needle biopsy. <i>Bulletin Du Cancer</i> , 2016, 103, 730-734.	1.6	7
374	Prostate cancer burden in Central and South America. <i>Cancer Epidemiology</i> , 2016, 44, S131-S140.	1.9	32
375	Lifestyle factors and prostate-specific antigen (PSA) testing in UK Biobank: Implications for epidemiological research. <i>Cancer Epidemiology</i> , 2016, 45, 40-46.	1.9	41
376	A DNA Hypermethylation Profile Independently Predicts Biochemical Recurrence Following Radical Prostatectomy. <i>Urologia Internationalis</i> , 2016, 97, 16-25.	1.3	7
377	Incidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide. <i>Prostate International</i> , 2016, 4, 118-124.	2.3	82
378	Evaluation of Prostate Cancer Bone Metastases with <sup>18</sup> F-NaF and <sup>18</sup> F-Fluorocholine PET/CT. <i>Journal of Nuclear Medicine</i> , 2016, 57, 55S-60S.	5.0	47
379	Cancer patterns and trends in Central and South America. <i>Cancer Epidemiology</i> , 2016, 44, S23-S42.	1.9	70
380	Anticancer effect of deoxypodophyllotoxin induces apoptosis of human prostate cancer cells. <i>Oncology Letters</i> , 2016, 12, 2918-2923.	1.8	17
381	Effects of cisplatin on the LSD1-mediated invasion and metastasis of prostate cancer cells. <i>Molecular Medicine Reports</i> , 2016, 14, 2511-2517.	2.4	6
382	Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study. <i>European Urology</i> , 2016, 70, 499-505.	1.9	6
383	Does comorbidity interact with prostate cancer to increase mortality? A Danish cohort study of 45 326 prostate cancer patients diagnosed during 1995-2011. <i>Acta Oncologica</i> , 2016, 55, 611-618.	1.8	10
384	The nomogram conundrum: a demonstration of why a prostate cancer risk model in Turkish men underestimates prostate cancer risk in the USA. <i>International Urology and Nephrology</i> , 2016, 48, 1623-1629.	1.4	1
385	Association between MMP-2 expression and prostate cancer: A meta-analysis. <i>Biomedical Reports</i> , 2016, 4, 241-245.	2.0	27
386	Impact of Genetic and Epigenetic Variations Within the FADS Cluster on the Composition and Metabolism of Polyunsaturated Fatty Acids in Prostate Cancer. <i>Prostate</i> , 2016, 76, 1182-1191.	2.3	24
387	Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 290-308.	329.8	644
388	The percentage of prostate-specific antigen (PSA) isoform [α <sup>2</sup> ]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≥65 years. <i>BJU International</i> , 2016, 117, 72-79.	2.5	55
389	Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy. <i>Modern Pathology</i> , 2016, 29, 1565-1574.	5.5	43



#	ARTICLE	IF	CITATIONS
390	Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. BMC Genomics, 2016, 17, 525.	2.8	172
391	Comprehensive autoencoder for prostate recognition on MR images. , 2016, , .		5
392	18F-NaF-PET/CT and 99mTc-MDP Bone Scintigraphy in the Detection of Bone Metastases in Prostate Cancer. Seminars in Nuclear Medicine, 2016, 46, 491-501.	4.6	98
393	Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation. Journal of Computer-Aided Molecular Design, 2016, 30, 1189-1200.	2.9	36
394	Effects of needle inner surface topography on friction and biopsy length. International Journal of Mechanical Sciences, 2016, 119, 412-418.	6.7	4
395	Altered miRNA expression in high-fat diet-induced prostate cancer progression. Carcinogenesis, 2016, 37, bgw108.	2.8	12
396	Smoking effect on secondary bladder cancer after external beam radiotherapy for prostate cancer. Japanese Journal of Clinical Oncology, 2016, 46, 952-957.	1.3	10
397	Does body mass index or subcutaneous adipose tissue thickness affect interfraction prostate motion in patients receiving radical prostate radiotherapy?. Journal of Radiotherapy in Practice, 2016, 15, 334-340.	0.5	1
398	Diagnostic and treatment factors associated with poor survival from prostate cancer are differentially distributed between regional and metropolitan Victoria, Australia. BMC Urology, 2016, 16, 54.	1.4	16
399	Psycho-oncology assessment in Chinese populations: a systematic review of quality of life and psychosocial measures. European Journal of Cancer Care, 2016, 25, 691-718.	1.5	1
400	International Trends in Prostate Cancer. , 2016, , 127-132.		0
401	Androgen Deprivation Therapy: Appropriate Patients, Timing to Initiate ADT, and Complications. , 2016, , 481-489.		0
402	INPP4B reverses docetaxel resistance and epithelial-to-mesenchymal transition via the PI3K/Akt signaling pathway in prostate cancer. Biochemical and Biophysical Research Communications, 2016, 477, 467-472.	2.1	21
403	Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries. European Urology, 2016, 70, 862-874.	1.9	392
404	The fast Pad $\hat{\mathcal{A}}$ transform for noisy magnetic resonance spectroscopic data from the prostate: potential contribution to individualized prostate cancer care. Journal of Mathematical Chemistry, 2016, 54, 707-764.	1.5	11
405	Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group. International Journal of Cancer, 2016, 138, 1388-1400.	5.1	216
406	Risk of malignant melanoma in men with prostate cancer: Nationwide, population-based cohort study. International Journal of Cancer, 2016, 138, 2154-2160.	5.1	13
407	A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation. European Urology, 2016, 69, 788-794.	1.9	140

#	ARTICLE	IF	CITATIONS
408	Prostate Cancer Registries: Current Status and Future Directions. <i>European Urology</i> , 2016, 69, 998-1012.	1.9	56
409	Time Trends in Histological Features of Latent Prostate Cancer in Japan. <i>Journal of Urology</i> , 2016, 195, 1415-1420.	0.4	25
410	Cohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base—a refined prostate cancer trajectory. <i>International Journal of Epidemiology</i> , 2016, 45, 73-82.	1.9	78
411	Comparison of Site of Death, Health Care Utilization, and Hospital Expenditures for Patients Dying With Cancer in 7 Developed Countries. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 272.	7.4	388
412	Características de los casos incidentes de cáncer de próstata en los últimos 5 años en un hospital de tercer nivel en México. <i>Revista Mexicana De Urología</i> , 2016, 76, 76-80.	0.0	3
413	Estimates of prostate cancer burden in Italy. <i>Cancer Epidemiology</i> , 2016, 40, 166-172.	1.9	10
414	Biphasic 68Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 898-905.	6.4	66
415	Global Cancer Incidence and Mortality Rates and Trends—An Update. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 16-27.	2.5	2,818
416	Development of Castration Resistant Prostate Cancer can be Predicted by a DNA Hypermethylation Profile. <i>Journal of Urology</i> , 2016, 195, 619-626.	0.4	42
417	Chemotherapy for metastatic castrate-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 139-144.	3.9	16
418	Active surveillance for prostate cancer. <i>International Journal of Urology</i> , 2016, 23, 211-218.	1.0	40
420	Quantitative proteomic study of human prostate cancer cells with different metastatic potentials. <i>International Journal of Oncology</i> , 2016, 48, 1437-1446.	3.3	21
421	Differences in the aggressiveness of prostate cancer among Korean, Caucasian, and African American men: A retrospective cohort study of radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 3.e9-3.e14.	1.6	40
422	Active surveillance for prostate cancer: a narrative review of clinical guidelines. <i>Nature Reviews Urology</i> , 2016, 13, 151-167.	3.8	139
423	Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1058-1064.	5.0	15
424	Cyclooxygenase 2 (rs2745557) Polymorphism and the Susceptibility to Benign Prostate Hyperplasia and Prostate Cancer in Egyptians. <i>Biochemical Genetics</i> , 2016, 54, 326-336.	1.7	6
425	Overexpression of long non-coding RNA LOC400891 promotes tumor progression and poor prognosis in prostate cancer. <i>Tumor Biology</i> , 2016, 37, 9603-9613.	1.8	24
426	Are strict vegetarians protected against prostate cancer?. <i>American Journal of Clinical Nutrition</i> , 2016, 103, 153-160.	4.7	75



#	ARTICLE	IF	CITATIONS
427	Prevalence and management of prostate cancer among East Asian men: Current trends and future perspectives. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 58.e1-58.e9.	1.6	17
428	MDV3100: Tritium labeling at high specific activity. <i>Applied Radiation and Isotopes</i> , 2016, 108, 35-37.	1.5	3
429	New Genetic Markers for Prostate Cancer. <i>Urologic Clinics of North America</i> , 2016, 43, 7-15.	1.8	12
430	Consultation audio-recording reduces long-term decision regret after prostate cancer treatment: A non-randomised comparative cohort study. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2016, 14, 308-314.	1.8	17
431	The Movember campaign: Impact on referral patterns and diagnosis of prostate cancer. <i>Scandinavian Journal of Public Health</i> , 2016, 44, 228-232.	2.3	54
432	Comparison of hybrid 68Ga-PSMA PET/MRI and 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 70-83.	6.4	148
433	The roles of stress and social support in prostate cancer mortality. <i>Scandinavian Journal of Urology</i> , 2016, 50, 47-55.	1.0	16
434	Men's use of networks to manage communication tensions related to a potential diagnosis of prostate cancer. <i>European Journal of Oncology Nursing</i> , 2016, 20, 106-112.	2.1	6
435	Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy. <i>World Journal of Urology</i> , 2016, 34, 261-267.	2.2	18
436	Prostate cancer mortality in Serbia, 1991–2010: a joinpoint regression analysis. <i>Journal of Public Health</i> , 2016, 38, e63-e67.	1.8	3
437	Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective. <i>European Journal of Cancer Care</i> , 2017, 26, e12505.	1.5	13
438	Increased Expression of ALDH1A1 in Prostate Cancer is Correlated With Tumor Aggressiveness: A Tissue Microarray Study of Iranian Patients. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017, 25, 592-598.	1.2	35
440	Active Surveillance for Favorable Risk Prostate Cancer in African Caribbean Men: Results of a Prospective Study. <i>Journal of Urology</i> , 2017, 197, 1229-1236.	0.4	10
441	Risk Stratification of Newly Diagnosed Prostate Cancer with Genomic Platforms. <i>Urology Practice</i> , 2017, 4, 322-328.	0.5	0
442	Litchi seed extracts diminish prostate cancer progression via induction of apoptosis and attenuation of EMT through Akt/GSK-3 $\beta$ signaling. <i>Scientific Reports</i> , 2017, 7, 41656.	3.3	58
443	In silico analysis of the deleterious nsSNPs (missense) in the homeobox domain of human HOXB13 gene responsible for hereditary prostate cancer. <i>Chemical Biology and Drug Design</i> , 2017, 90, 188-199.	3.2	9
444	Individual and Population-Based Screening. , 2017, , 43-55.		0
445	Epidemiology of Prostate Cancer in Europe: Patterns, Trends and Determinants. , 2017, , 1-27.		10

#	ARTICLE	IF	CITATIONS
446	Regret and fear in prostate cancer: The relationship between treatment appraisals and fear of recurrence in prostate cancer survivors. <i>Psycho-Oncology</i> , 2017, 26, 1825-1831.	2.3	19
447	High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer. <i>International Urology and Nephrology</i> , 2017, 49, 817-823.	1.4	42
448	Dual-responsive electrochemical immunosensor for prostate specific antigen detection based on Au-CoS/graphene and CeO <sub>2</sub> /ionic liquids doped with carboxymethyl chitosan complex. <i>Biosensors and Bioelectronics</i> , 2017, 94, 141-147.	10.1	70
449	The provision of dietary and physical activity advice for men diagnosed with prostate cancer: a qualitative study of the experiences and views of health care professionals, patients and partners. <i>Cancer Causes and Control</i> , 2017, 28, 319-329.	1.8	38
450	Long-term cancer control outcomes of robot-assisted radical prostatectomy for prostate cancer treatment: a meta-analysis. <i>International Urology and Nephrology</i> , 2017, 49, 995-1005.	1.4	19
451	Pros-IT CNR: an Italian prostate cancer monitoring project. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 165-172.	2.9	26
452	Environmental factors and risk of aggressive prostate cancer among a population of New Zealand men â€” a genotypic approach. <i>Molecular BioSystems</i> , 2017, 13, 681-698.	2.9	14
453	Cripto-1 promotes epithelial-mesenchymal transition in prostate cancer via Wnt/ $\beta^2$ -catenin signaling. <i>Oncology Reports</i> , 2017, 37, 1521-1528.	2.6	23
454	Measurement of serum isoform [ $\alpha^2$ ]proPSA derivatives shows superior accuracy to magnetic resonance imaging in the diagnosis of prostate cancer in patients with a total prostate-specific antigen level of $2 \times 10^{-6}$ ng/ml. <i>Scandinavian Journal of Urology</i> , 2017, 51, 251-257.	1.0	11
456	Low-dose-rate Brachytherapy for Prostate Cancer in Low-resource Settings. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 378-382.	0.8	0
457	Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy. <i>European Urology</i> , 2017, 72, 345-351.	1.9	16
458	The need for active surveillance for low risk prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 487-489.	2.4	3
459	Cancer incidence profile in sub-Saharan African-born blacks in the United States: Similarities and differences with US-born non-Hispanic blacks. <i>Cancer</i> , 2017, 123, 3116-3124.	4.1	22
460	Quality of sleep in patients receiving androgen deprivation therapy for prostate cancer. <i>Neurological Sciences</i> , 2017, 38, 1445-1451.	1.9	17
461	Autophagy activated by the c-Jun N-terminal kinase-mediated pathway protects human prostate cancer PC3 cells from celecoxib-induced apoptosis. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 2348-2354.	1.8	27
462	Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 352-360.	3.9	69
463	Multiparametric MRI/ultrasound fusion-guided biopsy decreases detection of indolent cancer in African-American men. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 348-351.	3.9	8
464	A Pooled Analysis of 15 Prospective Cohort Studies on the Association between Fruit, Vegetable, and Mature Bean Consumption and Risk of Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1276-1287.	2.5	27

#	ARTICLE	IF	CITATIONS
465	Tumour heterogeneity poses a significant challenge to cancer biomarker research. British Journal of Cancer, 2017, 117, 367-375.	6.4	110
466	Trends in net survival from prostate cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S114-S120.	1.3	4
467	Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: a systematic review and meta-analysis. Scientific Reports, 2017, 7, 2374.	3.3	30
468	MRI pathway and TRUS-guided biopsy for detecting clinically significant prostate cancer. The Cochrane Library, 2017, , .	2.8	2
469	Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Reports, 2017, 19, 2045-2059.	6.4	99
470	Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies. Current Urology Reports, 2017, 18, 48.	2.2	2
471	Therapy assessment of bone metastatic disease in the era of 223radium. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 84-96.	6.4	30
472	Race/ethnicity and criminal behavior: Neurohormonal influences. Journal of Criminal Justice, 2017, 51, 34-58.	2.3	6
473	Neutravidin biosensor for direct capture of dual-functional biotin-molecular beacon-AuNP probe for sensitive voltammetric detection of microRNA. Sensors and Actuators B: Chemical, 2017, 248, 77-84.	7.8	20
474	Active surveillance for prostate cancer: Is it ready for primetime in the Caribbean?. African Journal of Urology, 2017, 23, 89-93.	0.4	4
475	Cytokines are early diagnostic biomarkers of graft-versus-host disease in liver recipients. Hepatobiliary and Pancreatic Diseases International, 2017, 16, 45-51.	1.3	4
476	Involvement of apoptotic pathways in docosahexaenoic acid-induced benefit in prostate cancer: Pathway-focused gene expression analysis using RT2 Profile PCR Array System. Lipids in Health and Disease, 2017, 16, 59.	3.0	21
477	Elevated levels of epithelial cell transforming sequence 2 predicts poor prognosis for prostate cancer. Medical Oncology, 2017, 34, 13.	2.5	20
478	Comparison of free-hand transperineal mpMRI/TRUS fusion-guided biopsy with transperineal 12-core systematic biopsy for the diagnosis of prostate cancer: a single-center prospective study in China. International Urology and Nephrology, 2017, 49, 439-448.	1.4	36
479	Care-related predictors for negative intrusive thoughts after prostate cancer diagnosisâ€”data from the prospective LAPPRO trial. Psycho-Oncology, 2017, 26, 1749-1757.	2.3	5
480	Prostate cancer diagnostics: Clinical challenges and the ongoing need for disruptive and effective diagnostic tools. Biotechnology Advances, 2017, 35, 135-149.	11.7	57
481	Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up. Surgical Oncology, 2017, 26, 21-27.	1.6	8
482	To study the relationship between cadmium, zinc and mtDNA copy number in North Indian patients suffering from prostate cancer: A case control study. African Journal of Urology, 2017, 23, 126-132.	0.4	6

#	ARTICLE	IF	CITATIONS
483	Evaluation of expressed prostatic secretion and serum using surface-enhanced Raman spectroscopy for the noninvasive detection of prostate cancer, a preliminary study. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 1051-1059.	3.3	32
484	The impact of a family history of prostate cancer on the prognosis and features of the disease in Korea: results from a cross-sectional longitudinal pilot study. <i>International Urology and Nephrology</i> , 2017, 49, 2119-2125.	1.4	6
485	A multicentre randomised controlled trial assessing whether MRI-targeted biopsy is non-inferior to standard transrectal ultrasound guided biopsy for the diagnosis of clinically significant prostate cancer in men without prior biopsy: a study protocol. <i>BMJ Open</i> , 2017, 7, e017863.	1.9	14
486	Ten-year Mortality in Men With Nonmetastatic Prostate Cancer in Norway. <i>Urology</i> , 2017, 110, 140-147.	1.0	8
487	Lemur Tyrosine Kinase-3 Suppresses Growth of Prostate Cancer Via the AKT and MAPK Signaling Pathways. <i>Cellular Physiology and Biochemistry</i> , 2017, 42, 2582-2592.	1.6	7
488	Optimal preprocessing of serum and urine metabolomic data fusion for staging prostate cancer through design of experiment. <i>Analytica Chimica Acta</i> , 2017, 991, 68-75.	5.4	24
489	Prostate cancer clinical presentation, incidence, mortality and survival in Guadeloupe over the period 2008–2013 from a population-based cancer registry. <i>Cancer Causes and Control</i> , 2017, 28, 1265-1273.	1.8	21
490	Prostate cancer incidence and mortality in Portugal: trends, projections and regional differences. <i>European Journal of Cancer Prevention</i> , 2017, 26, 404-410.	1.3	6
491	Over-expression of $\beta$ -catenin is associated with high grade of prostatic cancer in Libyan patients. <i>African Journal of Urology</i> , 2017, 23, 133-138.	0.4	1
492	The cancer-associated cell migration protein TSPAN1 is under control of androgens and its upregulation increases prostate cancer cell migration. <i>Scientific Reports</i> , 2017, 7, 5249.	3.3	39
493	Physical after-effects in men undergoing prostate biopsy in routine clinical practice: Results from the PiCTure study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 604.e11-604.e16.	1.6	2
494	Diagnostic characteristics of lethal prostate cancer. <i>European Journal of Cancer</i> , 2017, 84, 18-26.	2.8	31
495	Prostate and breast cancer in four Nordic countries: A comparison of incidence and mortality trends across countries and age groups 1975–2013. <i>International Journal of Cancer</i> , 2017, 141, 2228-2242.	5.1	25
497	Cyclin-dependent kinase inhibitor 3 (CDKN3) plays a critical role in prostate cancer via regulating cell cycle and DNA replication signaling. <i>Biomedicine and Pharmacotherapy</i> , 2017, 96, 1109-1118.	5.6	42
498	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2017, , 883-923.		0
499	Prostate cancer incidence, mortality and survival trends in Estonia, 1995–2014. <i>Scandinavian Journal of Urology</i> , 2017, 51, 442-449.	1.0	9
500	Decreased expression of TCF12 contributes to progression and predicts biochemical recurrence in patients with prostate cancer. <i>Tumor Biology</i> , 2017, 39, 101042831770392.	1.8	13
501	Global Burden of Urologic Cancers, 1990–2013. <i>European Urology</i> , 2017, 71, 437-446.	1.9	248

#	ARTICLE	IF	CITATIONS
502	Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel. <i>Journal of Urology</i> , 2017, 197, 1041-1047.	0.4	23
503	Adult body size, sexual history and adolescent sexual development, may predict risk of developing prostate cancer: Results from the New South Wales Lifestyle and Evaluation of Risk Study (CLEAR). <i>International Journal of Cancer</i> , 2017, 140, 565-574.	5.1	30
504	Shorter GGN Repeats in Androgen Receptor Gene Would Not Increase the Risk of Prostate Cancer. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 159-166.	1.9	8
505	Cost-effectiveness analysis of multiparametric MRI with increased active surveillance for low-risk prostate cancer in Australia. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 1304-1315.	3.4	26
506	Comparing High-Intensity Focal Ultrasound Hemablation to Robotic Radical Prostatectomy in the Management of Unilateral Prostate Cancer: A Matched-Pair Analysis. <i>Journal of Endourology</i> , 2017, 31, 14-19.	2.1	39
507	Phytoestrogens and risk of prostate cancer: an updated meta-analysis of epidemiologic studies. <i>International Journal of Food Sciences and Nutrition</i> , 2017, 68, 28-42.	2.8	40
508	Combination of prostate imaging reporting and data system (<scp>PI</scp>â€<scp>RADS</scp>) score and prostateâ€specific antigen (<scp>PSA</scp>) density predicts biopsy outcome in prostate biopsy naâve patients. <i>BJU International</i> , 2017, 119, 225-233.	2.5	244
509	Men's helpâ€seeking in the first year after diagnosis of localised prostate cancer. <i>European Journal of Cancer Care</i> , 2017, 26, e12497.	1.5	45
510	Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 166, 16-27.	2.5	35
511	Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA. <i>Clinical Nutrition</i> , 2017, 36, 672-679.	5.0	65
512	Saturated fat intake and prostate cancer aggressiveness: results from the population-based North Carolina-Louisiana Prostate Cancer Project. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 48-54.	3.9	32
513	Prostate Specific Antigen and Prostate Cancer in Chinese Men Undergoing Initial Prostate Biopsies Compared with Western Cohorts. <i>Journal of Urology</i> , 2017, 197, 90-96.	0.4	44
514	Prostate cancer trends in Asia. <i>World Journal of Urology</i> , 2017, 35, 859-865.	2.2	19
515	Radiation Dosimetry for<sup>177</sup>Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions. <i>Journal of Nuclear Medicine</i> , 2017, 58, 445-450.	5.0	144
516	ProCare Trial: a phase <scp>II</scp> randomized controlled trial of shared care for followâup of men with prostate cancer. <i>BJU International</i> , 2017, 119, 381-389.	2.5	60
518	Prostate cancer screening in Europe and Asia. <i>Asian Journal of Urology</i> , 2017, 4, 86-95.	1.2	48
519	Impact of metformin on serum prostate-specific antigen levels. <i>Medicine (United States)</i> , 2017, 96, e9427.	1.0	8
520	Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer â€ The urologists' perspective. <i>Urological Science</i> , 2017, 28, 190-196.	0.6	5

#	ARTICLE	IF	CITATIONS
521	Dynamical Binding Modes Determine Agonistic and Antagonistic Ligand Effects in the Prostate-Specific G-Protein Coupled Receptor (PSGR). Scientific Reports, 2017, 7, 16007.	3.3	17
522	Stability analysis on the radioactive iodine-labelled prostate cancer-specific recombinant oncolytic adenovirus. Oncology Letters, 2017, 14, 6403-6408.	1.8	1
523	Nuclear magnetic resonance spectroscopy as a new approach for improvement of early diagnosis and risk stratification of prostate cancer. Journal of Zhejiang University: Science B, 2017, 18, 921-933.	2.8	14
524	Benchmarking life expectancy and cancer mortality: global comparison with cardiovascular disease 1981-2010. BMJ, The, 2017, 357, j2765.	6.0	50
525	Cancer: Global Burden, Trends, and Projections. , 2017, , 347-368.		0
526	High-fat diet-induced adipokine and cytokine alterations promote the progression of prostate cancer in $\Delta^2$ vivo and in $\Delta^2$ vitro. Oncology Letters, 2017, 15, 1607-1615.	1.8	21
527	Determinants of behavioral intentions to screen for prostate cancer in Omani men. Asia-Pacific Journal of Oncology Nursing, 2017, 4, 348-355.	1.6	8
529	THE ROLE OF THE CLINICAL AND MOLECULAR ASSAYS IN PROSTATE CANCER DETECTION. Asian Journal of Pharmaceutical and Clinical Research, 2017, 10, 11.	0.3	6
530	Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study. Cancer Management and Research, 2017, Volume 9, 789-800.	1.9	16
531	A Single Nucleotide Polymorphism in <i>HPGD</i> Gene Is Associated with Prostate Cancer Risk. Journal of Cancer, 2017, 8, 4083-4086.	2.5	9
532	A Molecular Modeling Study of the Hydroxyflutamide Resistance Mechanism Induced by Androgen Receptor Mutations. International Journal of Molecular Sciences, 2017, 18, 1823.	4.1	20
533	Clinical Significance of Measuring Global Hydroxymethylation of White Blood Cell DNA in Prostate Cancer: Comparison to PSA in a Pilot Exploratory Study. International Journal of Molecular Sciences, 2017, 18, 2465.	4.1	7
534	Prostate Cancer and Aspirin Use: Synopsis of the Proposed Molecular Mechanisms. Frontiers in Pharmacology, 2017, 8, 145.	3.5	25
535	Index-Based Dietary Patterns and the Risk of Prostate Cancer. Clinical Nutrition Research, 2017, 6, 229.	1.2	14
536	Physical activity and risk of prostate and bladder cancer in China: The South and East China case-control study on prostate and bladder cancer. PLoS ONE, 2017, 12, e0178613.	2.5	14
537	Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists' recommendations for active treatment or active surveillance: a randomized clinical utility trial. BMC Urology, 2017, 17, 51.	1.4	9
538	Detection rate of prostate cancer following biopsy among the northern Han Chinese population: a single-center retrospective study of 1022 cases. World Journal of Surgical Oncology, 2017, 15, 165.	1.9	13
539	<b>No change in the prevalence of latent prostate cancer over the last 10 years: a forensic autopsy study in <b>Japan <b>. Biomedical Research, 2017, 38, 307-312.	0.9	7



#	ARTICLE	IF	CITATIONS
540	Accuracy of Diffusion Weighted Images and MR Spectroscopy in Prostate Lesions – Our Experience with Endorectal Coil on 1.5 T MRI. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, TC10-TC14.	0.8	2
541	Early dutasteride monotherapy in men with detectable serum prostate-specific antigen levels following radical prostatectomy: A prospective trial. Investigative and Clinical Urology, 2017, 58, 98.	2.0	4
542	Open radical prostatectomy reproducing robot-assisted radical prostatectomy: Involving antegrade nerve sparing and continuous anastomosis. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2017, 43, 1043-1051.	1.5	7
543	Advances in Biomarkers for PCa Diagnostics and Prognostics – A Way towards Personalized Medicine. International Journal of Molecular Sciences, 2017, 18, 2193.	4.1	6
544	Effect of statins type on incident prostate cancer risk: a meta-analysis and systematic review. Asian Journal of Andrology, 2017, 19, 666.	1.6	32
545	Endogenous and exogenous testosterone and prostate cancer: decreased-, increased- or null-risk?. Translational Andrology and Urology, 2017, 6, 566-579.	1.4	33
546	BMI and serum lipid parameters predict increasing risk and aggressive prostate cancer in Chinese people. Oncotarget, 2017, 8, 66051-66060.	1.8	14
547	Erectile dysfunction, masculinity, and psychosocial outcomes: a review of the experiences of men after prostate cancer treatment. Translational Andrology and Urology, 2017, 6, 60-68.	1.4	68
548	Obesity was an independent risk factor for febrile infection after prostate biopsy. Medicine (United States), 2017, 96, 1000000.	1.0	7
549	Prostate cancer and the impact on couples: a qualitative metasynthesis. Supportive Care in Cancer, 2018, 26, 1703-1713.	2.2	25
550	A novel peptide/Fe <sub>3</sub> O <sub>4</sub> @SiO <sub>2</sub> -Au nanocomposite-based fluorescence biosensor for the highly selective and sensitive detection of prostate-specific antigen. Talanta, 2018, 179, 531-537.	5.5	37
551	MicroRNA-223-3p regulates cell chemo-sensitivity by targeting FOXO3 in prostatic cancer. Gene, 2018, 658, 152-158.	2.2	20
552	TGF- $\beta$ -induced epithelial-mesenchymal transition in prostate cancer cells is mediated via TRPM7 expression. Molecular Carcinogenesis, 2018, 57, 752-761.	2.7	42
553	Metformin combined with quercetin synergistically repressed prostate cancer cells via inhibition of VEGF/PI3K/Akt signaling pathway. Gene, 2018, 664, 50-57.	2.2	82
554	Geographic Differences in Baseline Prostate Inflammation and Relationship with Subsequent Prostate Cancer Risk: Results from the Multinational REDUCE Trial. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 783-789.	2.5	1
555	Adipose tissue: Critical contributor to the development of prostate cancer. Journal of Medical Investigation, 2018, 65, 9-17.	0.5	28
556	Paraneoplastic sensorimotor polyneuropathy in prostatic adenocarcinoma. Medicine (United States), 2018, 97, e0030.	1.0	3
557	Prostate-specific antigen screening impacts on biochemical recurrence in patients with clinically localized prostate cancer. International Journal of Urology, 2018, 25, 561-567.	1.0	2

#	ARTICLE	IF	CITATIONS
558	Coaching to support men in making informed choices about prostate cancer screening: A qualitative study. <i>Patient Education and Counseling</i> , 2018, 101, 872-877.	2.2	2
559	nNOS-positive minor-branches of the dorsal penile nerves is associated with erectile function in the bilateral cavernous injury model of rats. <i>Scientific Reports</i> , 2018, 8, 929.	3.3	14
560	Survival by Hispanic ethnicity among patients with cancer participating in SWOG clinical trials. <i>Cancer</i> , 2018, 124, 1760-1769.	4.1	9
561	Current work environments: What problems are being faced by Japanese urologists?. <i>International Journal of Urology</i> , 2018, 25, 327-336.	1.0	3
563	Matrine inhibits the progression of prostate cancer by promoting expression of GADD45B. <i>Prostate</i> , 2018, 78, 327-335.	2.3	34
564	Pathologic Outcomes of Candidates for Active Surveillance Undergoing Radical Prostatectomy: Results from a Contemporary Turkish Patient Cohort. <i>Urologia Internationalis</i> , 2018, 100, 43-49.	1.3	5
565	Assessment of Serum microRNA Biomarkers to Predict Reclassification of Prostate Cancer in Patients on Active Surveillance. <i>Journal of Urology</i> , 2018, 199, 1475-1481.	0.4	26
566	Are concurrent systematic cores needed at the time of targeted biopsy in patients with prior negative prostate biopsies?. <i>Progres En Urologie</i> , 2018, 28, 18-24.	0.8	10
567	Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 496-508.	6.4	152
568	The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date. <i>BJU International</i> , 2018, 121, 737-744.	2.5	51
569	Incidencia real de c�ncer de pr�stata en las �reas sanitarias de la comunidad aut�noma de Castilla y Le�n durante el a�o 2014. Datos del registro CAPCYL. <i>Actas Urol�gicas Espa�olas</i> , 2018, 42, 593-599.	0.7	2
570	Association between shift work and risk of prostate cancer: a systematic review and meta-analysis of observational studies. <i>Carcinogenesis</i> , 2018, 39, 87-97.	2.8	61
571	Prostate cancer screening: And the pendulum swings. <i>Cancer</i> , 2018, 124, 2890-2892.	4.1	2
572	Targeted Antimicrobial Prophylaxis Does Not Always Prevent Sepsis after Transrectal Prostate Biopsy. <i>Journal of Urology</i> , 2018, 200, 361-368.	0.4	27
573	Capillarisin blocks prostate�specific antigen expression on activation of androgen receptor in prostate carcinoma cells. <i>Prostate</i> , 2018, 78, 242-249.	2.3	9
574	Primary androgen deprivation therapy as monotherapy in unfavourable intermediate- and high-risk localised prostate cancer: a Singaporean single-centre perspective. <i>International Urology and Nephrology</i> , 2018, 50, 665-673.	1.4	3
575	Clinical comparison of the efficacy of three different bowel preparation methods on the infectious complications following transrectal ultrasonography�guided prostate biopsy in nursing practice. <i>Journal of Clinical Nursing</i> , 2018, 27, 2583-2589.	3.0	6
576	Oncologic Outcomes After Robot-assisted Radical Prostatectomy: A Large European Single-centre Cohort with Median 10-Year Follow-up. <i>European Urology Focus</i> , 2018, 4, 351-359.	3.1	32



#	ARTICLE	IF	CITATIONS
578	Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. <i>European Urology</i> , 2018, 73, 696-703.	1.9	45
579	Using Imaging to Predict Treatment Response in Genitourinary Malignancies. <i>European Urology Focus</i> , 2018, 4, 804-817.	3.1	3
580	Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade. <i>Prostate International</i> , 2018, 6, 18-23.	2.3	8
581	Predicting the cancer burden in Catalonia between 2015 and 2025: the challenge of cancer management in the elderly. <i>Clinical and Translational Oncology</i> , 2018, 20, 647-657.	2.4	12
582	Migration from Mexico to the United States: A high-speed cancer transition. <i>International Journal of Cancer</i> , 2018, 142, 477-488.	5.1	45
583	Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 89-100.	4.2	36
584	Ethnicity and ERG frequency in prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 125-131.	3.8	28
585	Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression. <i>European Urology</i> , 2018, 73, 322-339.	1.9	130
586	Role of robot-assisted radical prostatectomy in locally advanced prostate cancer. <i>International Journal of Urology</i> , 2018, 25, 30-35.	1.0	39
587	Evaluation of diffusion weighted imaging in the context of multi-parametric MRI of the prostate in the assessment of suspected low volume prostatic carcinoma. <i>Magnetic Resonance Imaging</i> , 2018, 47, 131-136.	1.8	1
588	Prognostic value of 18F- <sup>18</sup> F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 348-354.	6.4	22
589	LOX-1 activation by oxLDL triggers an epithelial mesenchymal transition and promotes tumorigenic potential in prostate cancer cells. <i>Cancer Letters</i> , 2018, 414, 34-43.	7.2	45
590	Actual incidence of prostate cancer in healthcare areas of the autonomous community of Castilla-León during 2014. CAPCYL registry data. <i>Actas Urológicas Españolas (English Edition)</i> , 2018, 42, 593-599.	0.2	0
591	Current and Future Burden of Prostate Cancer in Songkhla, Thailand: Analysis of Incidence and Mortality Trends From 1990 to 2030. <i>Journal of Global Oncology</i> , 2018, 4, 1-11.	0.5	7
592	Clinical significance of bromodomain-containing protein 7 and its association with tumor progression in prostate cancer. <i>Oncology Letters</i> , 2019, 17, 849-856.	1.8	6
593	Pattern of care of prostate cancer patients across the Martinique: results of a population-based study in the Caribbean. <i>BMC Cancer</i> , 2018, 18, 1130.	2.6	9
594	Human methionine synthase A2756G polymorphism increases susceptibility to prostate cancer. <i>Aging</i> , 2018, 10, 1776-1788.	3.1	27
595	A single-nucleotide polymorphism (rs1805087) in the methionine synthase (METH) gene increases the risk of prostate cancer. <i>Aging</i> , 2018, 10, 2741-2754.	3.1	3

#	ARTICLE	IF	CITATIONS
596	The Emerging Role of Epitranscriptomics in Cancer: Focus on Urological Tumors. <i>Genes</i> , 2018, 9, 552.	2.4	68
597	Predictive significance of TMRPSS2-ERG fusion in prostate cancer: a meta-analysis. <i>Cancer Cell International</i> , 2018, 18, 177.	4.1	37
598	Predictors of biochemical recurrence after radical prostatectomy in an Afro-Caribbean population in Guadeloupe (French West Indies). <i>Progres En Urologie</i> , 2018, 28, 442-449.	0.8	4
599	Profiling and bioinformatics analyses of differential circular RNA expression in prostate cancer cells. <i>Future Science OA</i> , 2018, 4, FSOA340.	1.9	21
600	Involvement of the glutamine RFamide peptide and its cognate receptor GPR103 in prostate cancer. <i>Oncology Reports</i> , 2018, 41, 1140-1150.	2.6	9
601	DT-13 Inhibits Proliferation and Metastasis of Human Prostate Cancer Cells Through Blocking PI3K/Akt Pathway. <i>Frontiers in Pharmacology</i> , 2018, 9, 1450.	3.5	29
602	Cancer Tsunami: Emerging Trends, Economic Burden, and Perioperative Implications. <i>Current Anesthesiology Reports</i> , 2018, 8, 348-354.	2.0	15
603	An update on emerging drugs for the treatment of erectile dysfunction. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 319-330.	2.4	13
604	FAM46B inhibits cell proliferation and cell cycle progression in prostate cancer through ubiquitination of $\beta$ -catenin. <i>Experimental and Molecular Medicine</i> , 2018, 50, 1-12.	7.7	23
605	Una mirada global y actualizada del c�ncer de pr�stata. <i>Revista Facultad De Medicina</i> , 2018, 66, 429-437.	0.2	2
606	Introduction to Prostate Cancer. , 2018, , 567-571.		0
607	miR-17-3p Downregulates Mitochondrial Antioxidant Enzymes and Enhances the Radiosensitivity of Prostate Cancer Cells. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 13, 64-77.	5.1	61
608	Differential expressions of integrin�linked kinase, $\beta$ -parvin and cofilin 1 in high�fat diet induced prostate cancer progression in a transgenic mouse model. <i>Oncology Letters</i> , 2018, 16, 4945-4952.	1.8	4
609	Mendelian randomization does not support serum calcium in prostate cancer risk. <i>Cancer Causes and Control</i> , 2018, 29, 1073-1080.	1.8	6
610	High levels of glioma tumor suppressor candidate region gene 1 predicts a poor prognosis for prostate cancer. <i>Oncology Letters</i> , 2018, 16, 6749-6755.	1.8	11
611	The effects of shared decision-making compared to usual care for prostate cancer screening decisions: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2018, 18, 1015.	2.6	13
612	Dynamic Contrast-Enhanced Imaging as a Prognostic Tool in Early Diagnosis of Prostate Cancer: Correlation with PSA and Clinical Stage. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-7.	0.8	11
613	ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer. <i>Cancer Prevention Research</i> , 2018, 11, 687-696.	1.5	32

#	ARTICLE	IF	CITATIONS
614	Prostate-specific antigen-based screening in Afro-Caribbean men: a survey of members of the Caribbean Urological Association. <i>Ecancermedalscience</i> , 2018, 12, 842.	1.1	4
615	The current state of prostate cancer treatment in Trinidad and Tobago. <i>Ecancermedalscience</i> , 2018, 12, 828.	1.1	2
616	Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients. <i>Clinical Epigenetics</i> , 2018, 10, 132.	4.1	21
617	Effects of age and comorbidity on survival vary according to risk grouping among patients with prostate cancer treated using radical prostatectomy. <i>Medicine (United States)</i> , 2018, 97, e12766.	1.0	5
618	Influence of symptoms of depression on the quality of life of men diagnosed with prostate cancer. <i>Revista Brasileira De Geriatria E Gerontologia</i> , 2018, 21, 70-78.	0.3	2
619	Risk factors for infectious complications following transrectal ultrasound-guided prostate biopsy. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 1491-1497.	2.7	19
620	Limb-bud and Heart Overexpression Inhibits the Proliferation and Migration of PC3M Cells. <i>Journal of Cancer</i> , 2018, 9, 424-432.	2.5	10
621	A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen $\geq 10$ ng/ml at Initial Biopsy. <i>European Urology</i> , 2018, 74, 731-738.	1.9	186
622	Is nonalcoholic fatty liver disease associated with the development of prostate cancer? A nationwide study with 10,516,985 Korean men. <i>PLoS ONE</i> , 2018, 13, e0201308.	2.5	34
623	Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location. <i>American Journal of Men's Health</i> , 2018, 12, 1807-1823.	1.6	303
624	Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 394-424.	329.8	62,121
625	Bidirectional Barbed Only <i>vs</i> Poliglecaprone Suture with Rhabdosphincter Reconstruction for Urethrovessical Anastomosis During Robotic Radical Prostatectomy: Does It Make Any Difference?. <i>Journal of Endourology</i> , 2018, 32, 944-949.	2.1	6
626	Antiarrhythmic drug usage and prostate cancer: a population-based cohort study. <i>Asian Journal of Andrology</i> , 2018, 20, 37.	1.6	10
627	Long non-coding RNA NAP1L6 promotes tumor progression and predicts poor prognosis in prostate cancer by targeting Inhibin- $\beta$ ; A. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4965-4977.	2.0	15
628	Elevated expression of PTCF3 correlates with tumor progression and predicts poor prognosis in patients with prostate cancer. <i>Molecular Medicine Reports</i> , 2018, 18, 3914-3922.	2.4	2
629	Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer. <i>Targeted Oncology</i> , 2018, 13, 649-655.	3.6	18
630	Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with <i>de novo</i> bone metastatic prostate cancer. <i>BJU International</i> , 2018, 122, 994-1002.	2.5	16
631	Spider peptide toxin lycosin-I induces apoptosis and inhibits migration of prostate cancer cells. <i>Experimental Biology and Medicine</i> , 2018, 243, 725-735.	2.4	13

#	ARTICLE	IF	CITATIONS
632	The burden of prostate cancer in Trinidad and Tobago: one of the highest mortality rates in the world. <i>Cancer Causes and Control</i> , 2018, 29, 685-697.	1.8	4
633	Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1873-1883.	6.4	41
634	Lu-177-PSMA treatment for metastatic prostate cancer: case examples of major responses. <i>Clinical and Translational Imaging</i> , 2018, 6, 223-237.	2.1	5
635	Exploring positive surgical margins after minimally invasive radical prostatectomy: Does body habitus really make a difference? <i>Progres En Urologie</i> , 2018, 28, 434-441.	0.8	4
636	HIF-1 $\alpha$ induces immune escape of prostate cancer by regulating NCR1/NKp46 signaling through miR-224. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 228-234.	2.1	39
637	Incidence and location of positive surgical margin among open, laparoscopic and robot-assisted radical prostatectomy in prostate cancer patients: a single institutional analysis. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 765-770.	1.3	22
638	Cancer detection rate of prebiopsy MRI with subsequent systematic and targeted biopsy are superior to non-targeting systematic biopsy without MRI in biopsy naïve patients: a retrospective cohort study. <i>BMC Urology</i> , 2018, 18, 51.	1.4	16
639	A population-based study of the influence of socioeconomic status on prostate cancer diagnosis in Taiwan. <i>International Journal for Equity in Health</i> , 2018, 17, 79.	3.5	10
640	The impact of moderate wine consumption on the risk of developing prostate cancer. <i>Clinical Epidemiology</i> , 2018, Volume 10, 431-444.	3.0	18
641	LPA1/3 signaling mediates tumor lymphangiogenesis through promoting CRT expression in prostate cancer. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2018, 1863, 1305-1315.	2.4	18
642	Association between dietary protein intake and prostate cancer risk: evidence from a meta-analysis. <i>World Journal of Surgical Oncology</i> , 2018, 16, 152.	1.9	13
643	Proton Beam Therapy Alone for Intermediate- or High-Risk Prostate Cancer: An Institutional Prospective Cohort Study. <i>Cancers</i> , 2018, 10, 116.	3.7	10
644	Platelet-Derived Growth Factor Receptor (PDGF-R) as the Target for Herbal-Based Anticancer Agents. , 2018, , 411-427.		0
645	Tobacco smoking and survival after a prostate cancer diagnosis: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 70, 30-40.	7.7	40
646	Targeting Splicing in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1287.	4.1	20
647	Carcinogenic potential of arylamine N-acetyltransferase in Asian populations. <i>Journal of Cancer Research and Practice</i> , 2018, 5, 131-135.	0.2	5
649	Exploring the Interaction Mechanism Between Cyclopeptide DC3 and Androgen Receptor Using Molecular Dynamics Simulations and Free Energy Calculations. <i>Frontiers in Chemistry</i> , 2018, 6, 119.	3.6	7
650	The utility and limitations of contrast-enhanced transrectal ultrasound scanning for the detection of prostate cancer in different area of prostate. <i>Clinical Hemorheology and Microcirculation</i> , 2018, 70, 281-290.	1.7	2

#	ARTICLE	IF	CITATIONS
651	Epidemiology of prostate cancer in Asian countries. <i>International Journal of Urology</i> , 2018, 25, 524-531.	1.0	260
652	Spectrophotometric photodynamic diagnosis of prostate cancer cells excreted in voided urine using 5-aminolevulinic acid. <i>Lasers in Medical Science</i> , 2018, 33, 1557-1563.	2.1	5
653	Treatment of hormone-naïve metastatic prostate cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2018, 12, 334-338.	1.3	3
654	Design and Fabrication of a Miniaturized Convex Array for Combined Ultrasound and Photoacoustic Imaging of the Prostate. <i>IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control</i> , 2018, 65, 2086-2096.	3.0	8
655	Development and validation of a novel automated Gleason grade and molecular profile that define a highly predictive prostate cancer progression algorithm-based test. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 594-603.	3.9	22
656	Metal/Metal Oxide Nanoparticles for Cancer Therapy. <i>Nanomedicine and Nanotoxicology</i> , 2018, , 341-364.	0.2	11
657	Autophagy induced by overexpression of DCTPP1 promotes tumor progression and predicts poor clinical outcome in prostate cancer. <i>International Journal of Biological Macromolecules</i> , 2018, 118, 599-609.	7.5	19
659	Coffee and tea consumption and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. <i>International Journal of Cancer</i> , 2019, 144, 240-250.	5.1	21
660	Treatment patterns of prostate cancer with bone metastasis in Beijing: A real-world study using data from an administrative claims database. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1501-1509.	1.9	5
661	Cancer control in the Caribbean island countries and territories: some progress but the journey continues. <i>Lancet Oncology</i> , The, 2019, 20, e503-e521.	10.7	25
662	Secretome profiling of PC3/nKR cells, a novel highly migrating prostate cancer subline derived from PC3 cells. <i>PLoS ONE</i> , 2019, 14, e0220807.	2.5	3
663	Epidemiology of Mortality Due to Prostate Cancer in Poland, 2000–2015. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2881.	2.6	7
665	miR-214-5p inhibits human prostate cancer proliferation and migration through regulating CRMP5. <i>Cancer Biomarkers</i> , 2019, 26, 193-202.	1.7	24
666	Global incidence comparisons and trends in ovarian germ cell tumors by geographic region in girls, adolescents and young women: 1988–2012. <i>Gynecologic Oncology</i> , 2019, 154, 608-615.	1.4	17
667	Diagnostic evaluation of diffusion kurtosis imaging for prostate cancer: Detection in a biopsy population. <i>European Journal of Radiology</i> , 2019, 118, 138-146.	2.6	6
668	Recent Advancements in aptamer-bioconjugates: Sharpening Stones for breast and prostate cancers targeting. <i>Journal of Drug Delivery Science and Technology</i> , 2019, 53, 101146.	3.0	23
669	&lt;p>Shared decision making for men facing prostate cancer treatment: a systematic review of randomized controlled trials&lt;p>. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 1153-1174.	1.8	16
670	The establishment of immune infiltration based novel recurrence predicting nomogram in prostate cancer. <i>Cancer Medicine</i> , 2019, 8, 5202-5213.	2.8	53

#	ARTICLE	IF	CITATIONS
671	Measurement of Sub-femtomolar Concentrations of Prostate-Specific Antigen through Single-Molecule Counting with an Upconversion-Linked Immunosorbent Assay. <i>Analytical Chemistry</i> , 2019, 91, 9435-9441.	6.5	62
672	Circulating microRNAs as potential diagnostic biomarkers and therapeutic targets in prostate cancer: Current status and future perspectives. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 16316-16329.	2.6	28
673	Phytochemicals in Prostate Cancer: From Bioactive Molecules to Upcoming Therapeutic Agents. <i>Nutrients</i> , 2019, 11, 1483.	4.1	59
674	<i>HOXC6</i> in the prognosis of prostate cancer. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 2715-2720.	2.8	21
675	Finnish sauna bathing does not increase or decrease the risk of cancer in men: A prospective cohort study. <i>European Journal of Cancer</i> , 2019, 121, 184-191.	2.8	6
676	Trends in urethral stricture management over two decades. <i>BJU International</i> , 2019, 124, 37-41.	2.5	7
677	Association of the extent of therapy with prostate cancer in those receiving testosterone therapy in a US commercial insurance claims database. <i>Clinical Endocrinology</i> , 2019, 91, 885-891.	2.4	10
678	Age, height, BMI and FBC predict prostate volume in ageing benign prostatic hyperplasia: Evidence from 5285 patients. <i>International Journal of Clinical Practice</i> , 2019, 73, e13438.	1.7	11
679	Overexpression levels of <i>cripto</i> predict poor prognosis in patients with prostate cancer following radical prostatectomy. <i>Oncology Letters</i> , 2019, 18, 2584-2591.	1.8	10
680	Glycosylation products in prostate diseases. <i>Clinica Chimica Acta</i> , 2019, 498, 52-61.	1.1	10
681	ICP-MS analysis of diet supplementation influence on the elemental content of rat prostate gland. <i>Monatshefte für Chemie</i> , 2019, 150, 1681-1690.	1.8	7
682	A systematic review and meta-analysis on incidence of prostate cancer in Iran. <i>Health Promotion Perspectives</i> , 2019, 9, 92-98.	1.9	8
683	A novel method for pain control: infiltration free local anesthesia technique (INFLATE) for transrectal prostatic biopsy using transcutaneous electrical nerve stimulation (TENS). <i>International Urology and Nephrology</i> , 2019, 51, 2119-2126.	1.4	10
684	Ultrasensitive electrochemical sensor for prostate specific antigen detection with a phosphorene platform and magnetic covalent organic framework signal amplifier. <i>Biosensors and Bioelectronics</i> , 2019, 144, 111691.	10.1	82
685	Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 1400.	2.4	16
686	Establishment of reference intervals for serum $\alpha$ -proPSA (p2PSA), %p2PSA and prostate health index in healthy men. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6453-6460.	2.0	5
687	HIF1 $\alpha$ promotes prostate cancer progression by increasing ATG5 expression. <i>Animal Cells and Systems</i> , 2019, 23, 326-334.	2.2	16
688	Discovery and Validation of Serum MicroRNAs as Early Diagnostic Biomarkers for Prostate Cancer in Chinese Population. <i>BioMed Research International</i> , 2019, 2019, 1-9.	1.9	28



#	ARTICLE	IF	CITATIONS
690	Chemoprevention of Prostate Cancer by Natural Agents: Evidence from Molecular and Epidemiological Studies. <i>Anticancer Research</i> , 2019, 39, 5231-5259.	1.1	52
691	Mitochondrial oncobioenergetics of prostate tumorigenesis (Review). <i>Oncology Letters</i> , 2019, 18, 4367-4376.	1.8	9
692	Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China. <i>Public Health</i> , 2019, 172, 70-80.	2.9	95
693	Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer. <i>Journal of Sexual Medicine</i> , 2019, 16, 872-879.	0.6	27
694	Tumor-derived nanovesicles promote lung distribution of the therapeutic nanovector through repression of Kupffer cell-mediated phagocytosis. <i>Theranostics</i> , 2019, 9, 2618-2636.	10.0	39
695	Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e814-e821.	1.9	12
696	Validated Prospective Assessment of Quality of Life After Robot-Assisted Laparoscopic Prostatectomy: Beyond Continence and Erections. <i>American Journal of Men's Health</i> , 2019, 13, 155798831985455.	1.6	7
697	Bone mineral density, structure, distribution and strength in men with prostate cancer treated with androgen deprivation therapy. <i>Bone</i> , 2019, 127, 367-375.	2.9	13
698	The American Cancer Society 2035 challenge goal on cancer mortality reduction. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 351-362.	329.8	49
699	Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men. <i>British Journal of Cancer</i> , 2019, 120, 1067-1074.	6.4	9
700	LncRNA TUC338 is overexpressed in prostate carcinoma and downregulates miR-466. <i>Gene</i> , 2019, 707, 224-230.	2.2	16
701	Comparison of orthogonal NLP methods for clinical phenotyping and assessment of bone scan utilization among prostate cancer patients. <i>Journal of Biomedical Informatics</i> , 2019, 94, 103184.	4.3	12
702	CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer. <i>British Journal of Cancer</i> , 2019, 120, 1120-1128.	6.4	25
703	Aspirin Exposure and Mortality Risk among Prostate Cancer Patients: A Systematic Review and Meta-Analysis. <i>BioMed Research International</i> , 2019, 2019, 1-15.	1.9	5
704	Appraising risk in active surveillance of localized prostate cancer. <i>Health Expectations</i> , 2019, 22, 1028-1039.	2.6	5
705	Distribution of Prostate Imaging Reporting and Data System score and diagnostic accuracy of magnetic resonance imaging-targeted biopsy: comparison of an Asian and European cohort. <i>Prostate International</i> , 2019, 7, 96-101.	2.3	3
706	Geographical Variations in Prostate Cancer Outcomes: A Systematic Review of International Evidence. <i>Frontiers in Oncology</i> , 2019, 9, 238.	2.8	62
707	Cancer burden in the Caribbean: an overview of the Martinique Cancer Registry profile. <i>BMC Cancer</i> , 2019, 19, 239.	2.6	19

#	ARTICLE	IF	CITATIONS
708	Stiffness of prostate gland measured by transrectal real-time shear wave elastography for detection of prostate cancer: a feasibility study. <i>British Journal of Radiology</i> , 2019, 92, 20180970.	2.2	21
709	The Proteogenomic Landscape of Curable Prostate Cancer. <i>Cancer Cell</i> , 2019, 35, 414-427.e6.	16.8	168
710	Persistent Homology for the Quantitative Evaluation of Architectural Features in Prostate Cancer Histology. <i>Scientific Reports</i> , 2019, 9, 1139.	3.3	47
711	A prostate-specific antigen electrochemical immunosensor based on Pd NPs functionalized electroactive Co-MOF signal amplification strategy. <i>Biosensors and Bioelectronics</i> , 2019, 132, 97-104.	10.1	93
712	Outpatient Robot-assisted Radical Prostatectomy: A Feasibility Study. <i>Urology</i> , 2019, 128, 16-22.	1.0	22
713	Efficacy and Safety of Combined Androgen Blockade with Antiandrogen for Advanced Prostate Cancer. <i>Current Oncology</i> , 2019, 26, 4203.	2.2	9
714	Modeling of mortality in elderly by prostate diseases in Brazil. <i>Communications in Statistics Case Studies Data Analysis and Applications</i> , 2019, 5, 11-16.	0.3	0
715	Trends in Prostate Cancer Prevalence and Radical Prostatectomy Rate according to Age Structural Changes in South Korea between 2005 and 2015. <i>Yonsei Medical Journal</i> , 2019, 60, 257.	2.2	5
716	Simulation on biomarker sensor miniaturization based on metamaterial. <i>Modern Physics Letters B</i> , 2019, 33, 1950135.	1.9	1
717	Do Canadian Radiation Oncologists Consider Geriatric Assessment in the Decision-Making Process for Treatment of Patients 80 years and Older with Non-Metastatic Prostate Cancer? â€“ National Survey. <i>Journal of Geriatric Oncology</i> , 2019, 10, 659-665.	1.0	9
718	The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer. <i>Urology</i> , 2019, 130, 1-12.	1.0	56
719	Prospective study of cancer in Japanese patients with type 2 diabetes: the Fukuoka Diabetes Registry. <i>Diabetology International</i> , 2019, 10, 260-267.	1.4	2
720	Overexpression of malignant brain tumor domain containing protein 1 predicts a poor prognosis of prostate cancer. <i>Oncology Letters</i> , 2019, 17, 4640-4646.	1.8	6
721	Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations. <i>European Urology Oncology</i> , 2019, 2, 277-285.	5.4	7
722	Incidence of Prostate Cancer according to Metabolic Health Status: a Nationwide Cohort Study. <i>Journal of Korean Medical Science</i> , 2019, 34, e49.	2.5	14
723	Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression. <i>EBioMedicine</i> , 2019, 40, 504-516.	6.1	21
724	Associations of CYP1 polymorphisms with risk of prostate cancer: an updated meta-analysis. <i>Bioscience Reports</i> , 2019, 39, .	2.4	8
725	Exonuclease 1 expression is associated with clinical progression, metastasis, and survival prognosis of prostate cancer. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 11383-11389.	2.6	28



#	ARTICLE	IF	CITATIONS
726	Deeply supervised 3D fully convolutional networks with group dilated convolution for automatic <scp>MRI</scp> prostate segmentation. Medical Physics, 2019, 46, 1707-1718.	3.0	151
727	Comparison of the periimplant bone stress distribution on three fixed partial supported prosthesis designs under different loading. A 3D finite element analysis. Journal of Experimental and Theoretical Artificial Intelligence, 2019, 31, 875-888.	2.8	0
728	Global Patterns and Trends in Pancreatic Cancer Incidence. Pancreas, 2019, 48, 199-208.	1.1	39
729	Trend and projection of mortality rate due to non-communicable diseases in Iran: A modeling study. PLoS ONE, 2019, 14, e0211622.	2.5	34
730	Detection of Clinically Significant Prostate Cancer Using Subharmonic Imaging. , 2019, , .		0
731	Prostate cancer incidence and mortality in the Baltic states, Belarus, the Russian Federation and Ukraine. BMJ Open, 2019, 9, e031856.	1.9	14
732	Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. The Cochrane Library, 2019, 2019, CD012663.	2.8	234
733	Individual Comparison of Cholesterol Metabolism in Normal and Tumour Areas in Radical Prostatectomy Specimens from Patients with Prostate Cancer: Results of the CHOMECA Study. European Urology Oncology, 2019, 2, 198-206.	5.4	5
734	Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer. European Urology Oncology, 2019, 2, 456-463.	5.4	13
735	Prognostic Value of CD1B in Localised Prostate Cancer. International Journal of Environmental Research and Public Health, 2019, 16, 4723.	2.6	16
736	Prostate Health Index outperforms other PSA derivatives in predicting a positive biopsy in men with tPSA <math>\leq 10</math> ng/mL. Journal of the Chinese Medical Association, 2019, 82, 772-777.	1.4	6
737	Prostate health index density predicts aggressive pathological outcomes after radical prostatectomy in Taiwanese patients. Journal of the Chinese Medical Association, 2019, 82, 835-839.	1.4	8
738	Recognition of Transrectal Ultrasound Prostate Image Based on HOG-LBP. , 2019, , .		7
739	Data-mining approach for screening of rare genetic elements associated with predisposition of prostate cancer in South-Asian populations. Biyokimya Dergisi, 2019, 44, 848-854.	0.5	3
740	Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications. Frontiers in Oncology, 2019, 9, 1287.	2.8	22
741	Long-term effects of radiation prior to surgery and chemotherapy on survival of esophageal cancer undergoing surgery. Medicine (United States), 2019, 98, e17617.	1.0	1
742	Changing Incidence and Stage Distribution of Prostate Cancer in a Lithuanian Population—Evidence from National PSA-Based Screening Program. International Journal of Environmental Research and Public Health, 2019, 16, 4856.	2.6	4
743	Role of surgery in oligometastatic prostate cancer. Prostate International, 2019, 7, 125-130.	2.3	15

#	ARTICLE	IF	CITATIONS
744	Serum insulin level, HOMA-IR and prostate cancer risk: A systematic review and meta-analysis. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 110-115.	3.6	17
745	Importance of androgen-deprivation therapy during enzalutamide treatment in men with metastatic castration-resistant prostate cancer following chemotherapy: results from retrospective, multicenter data. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 150-158.	3.9	6
746	Awareness and Attitudes of Nigerian Men Living in Abuja on Prostate Cancer and Screening. <i>Journal of Cancer Education</i> , 2019, 34, 1107-1111.	1.3	4
747	Imaging gastrin-releasing peptide receptors (GRPRs) in prostate cancer. <i>Clinical and Translational Imaging</i> , 2019, 7, 39-44.	2.1	5
748	Early Experience of Rechallenge <sup>177</sup> Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 644-648.	5.0	29
749	Outcomes of magnetic resonance imaging fusion-targeted biopsy of prostate imaging reporting and data system 3 lesions. <i>World Journal of Urology</i> , 2019, 37, 1581-1586.	2.2	18
751	Cabazitaxel inhibits prostate cancer cell growth by inhibition of androgen receptor and heat shock protein expression. <i>World Journal of Urology</i> , 2019, 37, 2137-2145.	2.2	11
752	Technologies for image-guided surgery for managing lymphatic metastases in prostate cancer. <i>Nature Reviews Urology</i> , 2019, 16, 159-171.	3.8	62
753	The history of cancer screening. <i>Current Problems in Surgery</i> , 2019, 56, 138-163.	1.1	12
754	MicroRNAs as prognostic markers in prostate cancer. <i>Prostate</i> , 2019, 79, 265-271.	2.3	25
755	The importance of targeting intracrinology in prostate cancer management. <i>World Journal of Urology</i> , 2019, 37, 751-757.	2.2	2
756	Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis. <i>Oncogene</i> , 2019, 38, 1751-1763.	5.9	61
757	Higher baseline dietary fat and fatty acid intake is associated with increased risk of incident prostate cancer in the SABOR study. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 244-251.	3.9	27
758	Novel metabolites from <i>Trichoderma atroviride</i> against human prostate cancer cells and their inhibitory effect on <i>Helicobacter pylori</i> and <i>Shigella</i> toxin producing <i>Escherichia coli</i> . <i>Microbial Pathogenesis</i> , 2019, 126, 19-26.	2.9	25
759	Usual adult occupation and risk of prostate cancer in West African men: the Ghana Prostate Study. <i>Occupational and Environmental Medicine</i> , 2019, 76, 71-77.	2.8	8
760	225Ac-PSMA-617 in chemotherapy-naïve patients with advanced prostate cancer: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 129-138.	6.4	249
761	Body mass index and prostate cancer risk in the Carotene and Retinol Efficacy Trial. <i>European Journal of Cancer Prevention</i> , 2019, 28, 212-219.	1.3	6
762	Phloretin Inhibits the Human Prostate Cancer Cells Through the Generation of Reactive Oxygen Species. <i>Pathology and Oncology Research</i> , 2020, 26, 977-984.	1.9	34

#	ARTICLE	IF	CITATIONS
763	Endocrine disrupting chemicals and biochemical recurrence of prostate cancer after prostatectomy: A cohort study in Guadeloupe (French West Indies). <i>International Journal of Cancer</i> , 2020, 146, 657-663.	5.1	19
764	A methodology for detecting relevant single nucleotide polymorphism in prostate cancer with multivariate adaptive regression splines and backpropagation artificial neural networks. <i>Neural Computing and Applications</i> , 2020, 32, 1231-1238.	5.6	7
765	Reduction of circular RNA Foxo3 promotes prostate cancer progression and chemoresistance to docetaxel. <i>Cancer Letters</i> , 2020, 468, 88-101.	7.2	127
766	Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework. <i>Social Science and Medicine</i> , 2020, 246, 112595.	3.8	23
767	Radical prostatectomy and simultaneous penile prosthesis implantation: a narrative review. <i>International Journal of Impotence Research</i> , 2020, 32, 274-280.	1.8	4
768	Outcomes for urologic oncology procedures: are there differences between academic and community hospitals?. <i>World Journal of Urology</i> , 2020, 38, 1187-1193.	2.2	5
769	Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. <i>European Urology</i> , 2020, 77, 38-52.	1.9	699
770	Biopsy Grade Group as a reliable prognostic factor for BCR in Afro-Caribbean men with intermediate- and high-risk prostate cancer. <i>World Journal of Urology</i> , 2020, 38, 1493-1499.	2.2	0
771	Ultra-effective near-infrared Photothermal therapy for the prostate cancer Nursing care through novel intended and surface tailored photo-responsive Ga-Au@MPS nanovesicles. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2020, 202, 111685.	3.8	14
772	Investigating the equivalent performance of biparametric compared to multiparametric MRI in detection of clinically significant prostate cancer. <i>Abdominal Radiology</i> , 2020, 45, 547-555.	2.1	10
773	ZEB1 activated-VPS9D1-AS1 promotes the tumorigenesis and progression of prostate cancer by sponging miR-4739 to upregulate MEF2D. <i>Biomedicine and Pharmacotherapy</i> , 2020, 122, 109557.	5.6	37
774	Whole-genome sequencing of prostate cancer reveals novel mutation-driven processes and molecular subgroups. <i>Life Sciences</i> , 2020, 254, 117218.	4.3	14
775	Appraising causal relationships of dietary, nutritional and physical-activity exposures with overall and aggressive prostate cancer: two-sample Mendelian-randomization study based on 79 prostate-cancer cases and 61 controls. <i>International Journal of Epidemiology</i> , 2020, 49, 587-596.	1.9	36
776	Optimal Starting Age and Baseline Level for Repeat Tests: Economic Concerns of PSA Screening for Chinese Men – 10-Year Experience of a Single Center. <i>Urologia Internationalis</i> , 2020, 104, 230-238.	1.3	7
777	Diagnostic Value of <sup>68</sup> Ga-PSMA PET/CT for Detection of Phosphatase and Tensin Homolog Expression in Prostate Cancer: A Pilot Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 873-880.	5.0	8
778	Transrectal Subharmonic Ultrasound Imaging for Prostate Cancer Detection. <i>Urology</i> , 2020, 138, 106-112.	1.0	8
779	Inhibition of let-7b-5p contributes to an anti-tumorigenic macrophage phenotype through the SOCS1/STAT pathway in prostate cancer. <i>Cancer Cell International</i> , 2020, 20, 470.	4.1	25
780	Retrospective Study of the Etiology and Risk Factors of Systemic Inflammatory Response Syndrome After Systematic Transrectal Ultrasound-Guided Prostate Biopsy. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 3187-3193.	2.7	1

#	ARTICLE	IF	CITATIONS
781	Preoperative Predictors of Biochemical Recurrence-Free Survival in High-Risk Prostate Cancer Following Radical Prostatectomy. <i>Frontiers in Oncology</i> , 2020, 10, 1761.	2.8	9
782	Circular RNA circ-0016068 Promotes the Growth, Migration, and Invasion of Prostate Cancer Cells by Regulating the miR-330-3p/BMI-1 Axis as a Competing Endogenous RNA. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 827.	3.7	34
783	Five lncRNAs Associated With Prostate Cancer Prognosis Identified by Coexpression Network Analysis. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382096357.	1.9	10
784	Prostate cancer awareness and screening practice among Kenyan men. <i>European Journal of Cancer Prevention</i> , 2020, 29, 252-258.	1.3	2
785	A novel and ultrasensitive sandwich-type electrochemical immunosensor based on delaminated MXene@AuNPs as signal amplification for prostate specific antigen (PSA) detection and immunosensor validation. <i>Talanta</i> , 2020, 220, 121403.	5.5	74
786	The prognostic value and potential mechanism of Matrix Metalloproteinases among Prostate Cancer. <i>International Journal of Medical Sciences</i> , 2020, 17, 1550-1560.	2.5	14
787	Multivariable Models Incorporating Multiparametric Magnetic Resonance Imaging Efficiently Predict Results of Prostate Biopsy and Reduce Unnecessary Biopsy. <i>Frontiers in Oncology</i> , 2020, 10, 575261.	2.8	4
788	The m6A methylation regulator-based signature for predicting the prognosis of prostate cancer. <i>Future Oncology</i> , 2020, 16, 2421-2432.	2.4	20
789	Prediction models for prostate cancer to be used in the primary care setting: a systematic review. <i>BMJ Open</i> , 2020, 10, e034661.	1.9	19
790	Characterization of Kinase Expression Related to Increased Migration of PC-3M Cells Using Global Comparative Phosphoproteome Analysis. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 543-553.	2.0	7
791	Melatonin and urological cancers: a new therapeutic approach. <i>Cancer Cell International</i> , 2020, 20, 444.	4.1	20
793	<p></p>The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 6821-6826.	1.9	8
794	Impact of organ confined prostate cancer treatment on quality of life. <i>Actas Urológicas Españolas (English Edition)</i> , 2020, 44, 630-636.	0.2	2
795	Aldehyde Dehydrogenases and Prostate Cancer: Shedding Light on Isoform Distribution to Reveal Druggable Target. <i>Biomedicines</i> , 2020, 8, 569.	3.2	8
796	Impacto en la calidad de vida del tratamiento del cáncer de próstata organoconfinado. <i>Actas Urológicas Españolas</i> , 2020, 44, 630-636.	0.7	1
797	Impact of 68Ga-PSMA PET/CT in the treatment of prostate cancer: Initial experience in Spain. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 405-411.	0.6	3
798	Temporal trends of kidney cancer incidence and mortality from 1990 to 2016 and projections to 2030. <i>Translational Andrology and Urology</i> , 2020, 9, 166-181.	1.4	21
799	A qualitative exploration of South African men's perceived effects of Androgen Deprivation Therapy (ADT) as a treatment for advanced prostate cancer. <i>Aging Male</i> , 2020, 23, 1266-1274.	1.9	1

#	ARTICLE	IF	CITATIONS
800	A Custom Genotyping Array Reveals Population-Level Heterogeneity for the Genetic Risks of Prostate Cancer and Other Cancers in Africa. <i>Cancer Research</i> , 2020, 80, 2956-2966.	0.9	25
801	Fabrication of a novel electrochemical aptasensor assisted by a novel computerized monitoring system for real-time determination of the prostate specific antigen: A computerized experimental method brought elegancy. <i>Microchemical Journal</i> , 2020, 157, 104898.	4.5	24
802	Cardiovascular diseases and metabolic abnormalities associated with obesity: What is the role of inflammatory responses? A systematic review. <i>Microvascular Research</i> , 2020, 131, 104023.	2.5	44
803	Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. <i>Translational Andrology and Urology</i> , 2020, 9, 196-209.	1.4	12
804	Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and externalâ€beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an openâ€label, randomized, phase 3 trial. <i>Cancer</i> , 2020, 126, 3961-3971.	4.1	6
805	Forensic Autopsies can Determine Latent Prostate Cancer Prevalence. <i>Journal of Forensic Sciences</i> , 2020, 65, 1557-1562.	1.6	1
807	Recyclable SERS-Based Immunoassay Guided by Photocatalytic Performance of Fe3O4@TiO2@Au Nanocomposites. <i>Biosensors</i> , 2020, 10, 25.	4.7	22
808	Family history in primary hormone therapy for prostate cancer: Analysis from a communityâ€based multiâ€institutional Japanâ€wide database. <i>International Journal of Urology</i> , 2020, 27, 313-318.	1.0	6
809	Screening key miRNAs and genes in prostate cancer by microarray analysis. <i>Translational Cancer Research</i> , 2020, 9, 856-868.	1.0	5
810	Improved therapeutic efficiency of photothermal treatment and nursing care in prostate cancer by DOX loaded PEG coated Cu@Se nano-hybrid vesicle. <i>Process Biochemistry</i> , 2020, 92, 78-84.	3.7	7
811	Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets. <i>JCO Global Oncology</i> , 2020, 6, 382-386.	1.8	21
812	Perioperative outcomes of robot-assisted laparoscopic radical prostatectomy (RALRP) and LRP in patients with prostate cancer based on risk groups. <i>Arab Journal of Urology Arab Association of Urology</i> , 2020, 18, 187-193.	1.5	1
813	Detection of prostate cancer using prostate imaging reporting and data system score and prostate-specific antigen density in biopsy-naïve and prior biopsy-negative patients. <i>Prostate International</i> , 2020, 8, 125-129.	2.3	11
814	Incorporating competing risk theory into evaluations of changes in cancer survival: making the most of cause of death and routinely linked sociodemographic data. <i>BMC Public Health</i> , 2020, 20, 1002.	2.9	1
815	Tomato consumption and intake of lycopene as predictors of the incidence of prostate cancer: the Adventist Health Study-2. <i>Cancer Causes and Control</i> , 2020, 31, 341-351.	1.8	24
816	Influence of Diet and Nutrition on Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1447.	4.1	99
817	Shift Work and Prostate Cancer: An Updated Systematic Review and Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1345.	2.6	18
818	Sin1 promotes proliferation and invasion of prostate cancer cells by modulating mTORC2-AKT and AR signaling cascades. <i>Life Sciences</i> , 2020, 248, 117449.	4.3	8

#	ARTICLE	IF	CITATIONS
819	Updates in Histologic Grading of Urologic Neoplasms. Archives of Pathology and Laboratory Medicine, 2020, 144, 335-343.	2.5	12
820	In silico studies of piperazine derivatives as potent anti-proliferative agents against PC-3 prostate cancer cell lines. Heliyon, 2020, 6, e03273.	3.2	6
821	Prostate Cancer in Latin America: Challenges and Recommendations. Cancer Control, 2020, 27, 107327482091572.	1.8	7
822	Functional summaries of persistence diagrams. Journal of Applied and Computational Topology, 2020, 4, 211-262.	2.0	41
824	Incidence of prostate cancer in Eritrea: Data from the National Health Laboratory, Orotta Referral Hospital and Sembel Hospital 2011-2018. PLoS ONE, 2020, 15, e0232091.	2.5	3
825	Characterization of the prognostic values and response to immunotherapy/chemotherapy of KrÄppel-like factors in prostate cancer. Journal of Cellular and Molecular Medicine, 2020, 24, 5797-5810.	3.6	24
826	Quantifying the effect of biopsy lateral decubitus patient positioning compared to supine prostate MRI scanning on prostate translocation and distortion. Canadian Urological Association Journal, 2020, 14, E445-E452.	0.6	1
827	Sulfiredoxin as a Potential Therapeutic Target for Advanced and Metastatic Prostate Cancer. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-12.	4.0	14
828	Human microbiome and prostate cancer development: current insights into the prevention and treatment. Frontiers of Medicine, 2021, 15, 11-32.	3.4	17
829	Sensors for diagnosis of prostate cancer: Looking beyond the prostate specific antigen. Biosensors and Bioelectronics, 2021, 173, 112790.	10.1	41
830	Cytopathic effects and local immune responses in repeated neoadjuvant HSV-tk + ganciclovir gene therapy for prostate cancer. Asian Journal of Urology, 2021, 8, 280-288.	1.2	3
831	Early outcomes of robot-assisted radical prostatectomy following completion of a structured training curriculum: a single surgeon cohort study. Journal of Clinical Urology, 2021, 14, 246-254.	0.1	0
832	KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy. Prostate Cancer and Prostatic Diseases, 2021, 24, 362-369.	3.9	8
833	Rising Prostate Cancer Incidence in Sub-Saharan Africa: A Trend Analysis of Data from the African Cancer Registry Network. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 158-165.	2.5	33
834	“More men die with prostate cancer than because of it” – an old adage that still holds true in the 21st century.. Cancer Treatment and Research Communications, 2021, 26, 100225.	1.7	11
835	GTSE1 promotes prostate cancer cell proliferation via the SP1/FOXM1 signaling pathway. Laboratory Investigation, 2021, 101, 554-563.	3.7	13
836	Research progress on the relationship between sex hormone-binding globulin and male reproductive system diseases. Andrologia, 2021, 53, e13893.	2.1	12
837	Toenail selenium, plasma selenoprotein P and risk of advanced prostate cancer: A nested case-control study. International Journal of Cancer, 2021, 148, 876-883.	5.1	9



#	ARTICLE	IF	CITATIONS
838	How to implement the requirements of a quality assurance system for prostate cancer. World Journal of Urology, 2021, 39, 41-47.	2.2	1
839	Do antispasmodics or rectal enemas improve image quality on multiparametric prostate MRI? An "Evidence-Based Practice"™ review of the literature. Abdominal Radiology, 2021, 46, 2770-2778.	2.1	11
840	Combination prostate cancer therapy: Prostate-specific membranes antigen targeted, pH-sensitive nanoparticles loaded with doxorubicin and tanshinone. Drug Delivery, 2021, 28, 1132-1140.	5.7	26
841	Global Burden of Cancer. , 2021, , 459-494.		0
842	Development and Validation of an Individualized Immune Prognostic Signature for Recurrent Prostate Cancer. Combinatorial Chemistry and High Throughput Screening, 2021, 24, 98-108.	1.1	1
843	Geographical variations of socioeconomic status and prostate cancer mortality in Taiwan. Cancer Causes and Control, 2021, 32, 203-210.	1.8	2
844	Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer. Cancer Reports, 2021, 4, e1334.	1.4	5
845	Supportive care needs of men with prostate cancer after hospital discharge: multi-stakeholder perspectives. International Journal of Qualitative Studies on Health and Well-being, 2021, 16, 1960706.	1.6	1
846	Long Noncoding RNA Small Nucleolar RNA Host Gene 3 Mediates Prostate Cancer Migration, Invasion, and Epithelial-Mesenchymal Transition by Sponging miR-487a-3p to Regulate <i>TRIM25</i>. Cancer Biotherapy and Radiopharmaceuticals, 2022, 37, 451-465.	1.0	7
847	PSA density in the diagnosis of prostate cancer in the Chinese population: results from the Chinese Prostate Cancer Consortium. Asian Journal of Andrology, 2021, 23, 300.	1.6	2
848	Histopathological diagnoses and patterns in transrectal ultrasound-guided prostatic biopsy series from a large tertiary care center in Saudi Arabia. Urology Annals, 2021, 13, 101.	0.6	0
849	The multiple effects of aspirin in prostate cancer patients. Cancer Treatment and Research Communications, 2021, 26, 100267.	1.7	12
850	Five-gene signature associating with Gleason score serve as novel biomarkers for identifying early recurring events and contributing to early diagnosis for Prostate Adenocarcinoma. Journal of Cancer, 2021, 12, 3626-3647.	2.5	11
851	Comprehensive analysis of tumour mutational burden and its clinical significance in prostate cancer. BMC Urology, 2021, 21, 29.	1.4	15
852	Impact on prostate cancer clinical presentation after non-screening policies at a tertiary-care medical center- a retrospective study. BMC Urology, 2021, 21, 20.	1.4	1
853	Transrectal Ultrasound and Photoacoustic Imaging Probe for Diagnosis of Prostate Cancer. Sensors, 2021, 21, 1217.	3.8	7
854	Hypoxia-mediated down-regulation of miRNAs™ biogenesis promotes tumor immune escape in bladder cancer. Clinical and Translational Oncology, 2021, 23, 1678-1687.	2.4	3
855	Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer. Drug Design, Development and Therapy, 2021, Volume 15, 639-649.	4.3	6



#	ARTICLE	IF	CITATIONS
856	Hypofractionated versus conventionally fractionated image-guided volumetric-modulated arc radiotherapy for localized prostate cancer: a phase II randomized trial from China. <i>Aging</i> , 2021, 13, 6936-6944.	3.1	3
857	Meningioma uptake of <sup>68</sup> Gallium-PSMA-11 as a pitfall on positron emission tomography/computer tomography. <i>Acta Radiologica Open</i> , 2021, 10, 205846012098100.	0.6	4
858	Men in rural Nigeria have a poor perception of prostate cancer risk; Hence they seldom seek screening. <i>Psycho-Oncology</i> , 2021, 30, 773-779.	2.3	4
859	Identification of Co-Deregulated Genes in Urinary Bladder Cancer Using High-Throughput Methodologies. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 1785.	2.5	0
860	Dietary Factors and Prostate Cancer Development, Progression, and Reduction. <i>Nutrients</i> , 2021, 13, 496.	4.1	47
861	Emerging role of multiparametric magnetic resonance imaging in identifying clinically relevant localized prostate cancer. <i>Current Opinion in Oncology</i> , 2021, 33, 244-251.	2.4	4
862	Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 209-249.	329.8	52,977
863	Cardiorespiratory fitness is not associated with reduced risk of prostate cancer: A cohort study and review of the literature. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13545.	3.4	3
864	Pathogenic mechanisms and the potential clinical value of circFoxo3 in cancers. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 23, 908-917.	5.1	13
865	Knowledge-based inverse treatment planning for low-dose-rate prostate brachytherapy. <i>Medical Physics</i> , 2021, 48, 2108-2117.	3.0	4
866	EWI-2 controls nucleocytoplasmic shuttling of EGFR signaling molecules and miRNA sorting in exosomes to inhibit prostate cancer cell metastasis. <i>Molecular Oncology</i> , 2021, 15, 1543-1565.	4.6	17
867	Electrochemical Detection of Prostate Cancer Biomarker PCA3 Using Specific RNA-Based Aptamer Labelled with Ferrocene. <i>Chemosensors</i> , 2021, 9, 59.	3.6	23
868	A systematic review and meta-analysis of unplanned hospital visits and re-admissions following radical prostatectomy for prostate cancer. <i>Canadian Urological Association Journal</i> , 2021, 15, E531-E544.	0.6	5
869	BZW1 promotes cell proliferation in prostate cancer by regulating TGF- $\beta$ 1/Smad pathway. <i>Cell Cycle</i> , 2021, 20, 894-902.	2.6	10
870	Consensus on the Screening, Staging, Treatment, and Surveillance of Localized, Recurrent, and Metastatic Prostate Cancer: The First Global Prostate Cancer Consensus Conference for Developing Countries. <i>JCO Global Oncology</i> , 2021, 7, 512-515.	1.8	2
872	Organochlorine pesticide exposure and risk of prostate cancer development and progression: a systematic review. <i>F1000Research</i> , 0, 10, 262.	1.6	1
873	Clinical Perspectives of Theranostics. <i>Molecules</i> , 2021, 26, 2232.	3.8	16
874	Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities. <i>Molecules</i> , 2021, 26, 2506.	3.8	87

#	ARTICLE	IF	CITATIONS
875	Determinants of the number of deaths from COVID-19: differences between low-income and high-income countries in the initial stages of the pandemic. <i>International Journal of Social Economics</i> , 2021, 48, 1229-1244.	1.9	9
876	Current Trends in Prevalence and Role of Long Noncoding RNA and Gene Fusion in Prostate Cancer: An Overview. <i>Annals of the National Academy of Medical Sciences (India)</i> , 2021, 57, 93-101.	0.3	0
877	How Has Prostate Cancer Radiotherapy Changed in Italy between 2004 and 2011? An Analysis of the National Patterns-Of-Practice (POP) Database by the Uro-Oncology Study Group of the Italian Society of Radiotherapy and Clinical Oncology (AIRO). <i>Cancers</i> , 2021, 13, 2702.	3.7	4
878	CLICK-enabled analogues reveal pregnenolone interactomes in cancer and immune cells. <i>IScience</i> , 2021, 24, 102485.	4.1	6
879	Correlation of the Grade Group of Prostate Cancer according to the International Society of Urological Pathology (Isup) 2014 Classification between Prostate Biopsy and Radical Prostatectomy Specimens. <i>Cancer Investigation</i> , 2021, 39, 521-528.	1.3	1
880	A Prospective Study on the Efficacy of Cognitive Targeted Transrectal Ultrasound Prostate Biopsy in Diagnosing Clinically Significant Prostate Cancer. <i>Research and Reports in Urology</i> , 2021, Volume 13, 207-213.	1.0	0
881	The Epidemiology of Prostate Cancer. , 0, , 1-16.		19
882	Differences in Prostate Cancer Incidence and Mortality in Lower Saxony (Germany) and Groningen Province (Netherlands): Potential Impact of Prostate-Specific Antigen Testing. <i>Frontiers in Oncology</i> , 2021, 11, 681006.	2.8	4
883	Effect of pre-operative internal obturator muscle mass index in MRI on biochemical recurrence of prostate cancer patients after radical prostatectomy: a multi-center study. <i>BMC Urology</i> , 2021, 21, 85.	1.4	1
884	Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial. <i>Cancer Medicine</i> , 2021, 10, 3240-3248.	2.8	3
885	Bioinformatics Analysis of GFAP as a Potential Key Regulator in Different Immune Phenotypes of Prostate Cancer. <i>BioMed Research International</i> , 2021, 2021, 1-13.	1.9	1
886	Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up. <i>European Urology Open Science</i> , 2021, 28, 43-46.	0.4	2
887	Temporal changes in cause-specific death in men with localised prostate cancer treated with radical prostatectomy: a population-based, nationwide study. <i>Journal of Surgical Oncology</i> , 2021, 124, 867-875.	1.7	1
889	Prostate Cancer Screening in Brazil: a single center experience in the public health system. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2021, 47, 558-565.	1.5	6
890	Commentary: Treatment of prostate cancer. <i>Current Urology</i> , 2021, 15, 77-78.	0.6	1
891	Blood and urine biomarkers in prostate cancer: Are we ready for reflex testing in men with an elevated prostate-specific antigen?. <i>Asian Journal of Urology</i> , 2021, 8, 343-353.	1.2	12
892	Basic factors predicting prostate cancer in Prostate Imaging Reporting and Data System-3 lesions. <i>Yeni Acerooloji Dergisi</i> , 2021, 16, 184-189.	0.1	1
893	Quantitative ultrasound shear wave elastography (USWE)-measured tissue stiffness correlates with PIRADS scoring of MRI and Gleason score on whole-mount histopathology of prostate cancer: implications for ultrasound image-guided targeting approach. <i>Insights Into Imaging</i> , 2021, 12, 96.	3.4	8

#	ARTICLE	IF	CITATIONS
894	Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer. Scientific Reports, 2021, 11, 14131.	3.3	4
895	Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. Cancer Treatment Reviews, 2021, 98, 102206.	7.7	30
896	Determination of sarcosine based on magnetic cross-linked enzyme aggregates for diagnosis of prostate cancer. Biochemical Engineering Journal, 2021, 172, 108039.	3.6	6
897	CARDIOVASCULAR RISK ASSOCIATED WITH ANDROGEN DEPRIVATION THERAPY IN ADVANCED PROSTATE CANCER. Asian Journal of Pharmaceutical and Clinical Research, 0, , 6-9.	0.3	0
898	Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention. Pharmaceutics, 2021, 13, 1195.	4.5	32
899	Prognostic Value of miR-1826 in Prostate Cancer and Its Regulatory Effect on Tumor Progression. OncoTargets and Therapy, 2021, Volume 14, 4467-4475.	2.0	1
900	Transvaginal subfascial synthetic sling “ a novel technique” versus trans-obturator mid-urethral sling in female stress urinary incontinence: A comparative study. Current Urology, 2021, 15, 143-147.	0.6	1
901	Combination Therapy of Metastatic Castration-Recurrent Prostate Cancer: Hyaluronic Acid Decorated, Cabazitaxel-Prodrug and Orlistat Co-Loaded Nano-System. Drug Design, Development and Therapy, 2021, Volume 15, 3605-3616.	4.3	12
902	Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	1.4	17
903	Basic Science and Molecular Genetics of Prostate Cancer Aggressiveness. Urologic Clinics of North America, 2021, 48, 339-347.	1.8	5
904	Covalent organic frameworks: Advances in synthesis and applications. Materials Today Communications, 2021, 28, 102612.	1.9	18
905	Patient-Specific Dosimetry in Radioligand Therapy (RLT) for Metastatic Prostate Cancer Using <sup>177</sup> Lu-DKFZ-PSMA-617. Nuclear Medicine and Molecular Imaging, 2021, 55, 237-244.	1.0	2
906	The emerging landscape of tumor marker panels for the identification of aggressive prostate cancer: the perspective through bibliometric analysis of an Italian translational working group in uro-oncology. Minerva Urology and Nephrology, 2021, 73, 442-451.	2.5	23
907	Early detection of prostate cancer in firefighters: a register-based study of prognostic factors and survival. Occupational and Environmental Medicine, 2021, , oemed-2021-107622.	2.8	4
908	Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate IntelliScore test in three independent prospective studies. Prostate Cancer and Prostatic Diseases, 2022, 25, 296-301.	3.9	40
909	The paradoxical role of matrix metalloproteinase-11 in cancer. Biomedicine and Pharmacotherapy, 2021, 141, 111899.	5.6	20
910	Association between <i>Helicobacter pylori</i> infection and mortality risk in prostate cancer patients receiving androgen deprivation therapy: A real-world evidence study. Cancer Medicine, 2021, 10, 8162-8171.	2.8	4
911	Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study. BMC Urology, 2021, 21, 131.	1.4	7

#	ARTICLE	IF	CITATIONS
912	The role of regulatory T cells in the pathogenesis and treatment of prostate cancer. Life Sciences, 2021, 284, 119132.	4.3	26
913	Cost-Effectiveness Analysis of Prostate Cancer Screening in Brazil. Value in Health Regional Issues, 2021, 26, 89-97.	1.2	1
914	A case-control study investigating the association of TP53 rs1042522 and CDH1 rs16260 polymorphisms with prostate cancer risk. Meta Gene, 2021, 30, 100962.	0.6	1
915	Assessment of daily dose accumulation for robustly optimized intensity modulated proton therapy treatment of prostate cancer. Physica Medica, 2021, 81, 77-85.	0.7	4
916	Muscleblind-like 1 antisense RNA 1 inhibits cell proliferation, invasion, and migration of prostate cancer by sponging miR-181a-5p and regulating PTEN/PI3K/AKT/mTOR signaling. Bioengineered, 2021, 12, 803-814.	3.2	28
917	Milk Consumption and Prostate Cancer: A Systematic Review. World Journal of Men's Health, 2021, 39, 419.	3.3	6
918	Nuclear Medicine Modalities to Image Bone Metastases with Bone-Targeting Agents: Conventional Scintigraphy and Positron-Emission Tomography. , 2017, , 61-74.		1
919	Racial Differences. Molecular Pathology Library, 2018, , 79-98.	0.1	1
921	Germline Genetic Variants Associated with Prostate Cancer and Potential Relevance to Clinical Practice. Recent Results in Cancer Research, 2014, 202, 9-26.	1.8	12
922	Review of recent applications of the conventional and derivative fast Pad <sup>Å</sup> transform for magnetic resonance spectroscopy. Journal of Mathematical Chemistry, 2019, 57, 385-464.	1.5	15
923	In vivo comparison of the proangiogenic properties of chlordecone and three of its dechlorinated derivatives formed by in situ chemical reduction. Environmental Science and Pollution Research, 2020, 27, 40953-40962.	5.3	3
924	Tailored Biofunctionalized Biosensor for the Label-Free Sensing of Prostate-Specific Antigen. ACS Applied Bio Materials, 2020, 3, 7821-7830.	4.6	36
925	Updated results from the European Randomized Study of Prostate-Specific Antigen (PSA) Screening for Prostate Cancer: are Asian countries encouraged to promote PSA screening?. Asian Journal of Andrology, 2012, 14, 522-524.	1.6	5
926	Interracial differences in prostate cancer progression among patients from the United States, China and Japan. Asian Journal of Andrology, 2013, 15, 705-707.	1.6	12
927	Predictive value of different prostate-specific antigen-based markers in men with baseline total prostate-specific antigen <2.0 ng/mL. International Journal of Urology, 2017, 24, 602-609.	1.0	6
928	Automatic MRI prostate segmentation using 3D deeply supervised FCN with concatenated atrous convolution. , 2019, , .		7
929	Antibiotic prophylaxis for transrectal ultrasound-guided prostatic biopsies: a comparison of two regimens. African Journal of Urology, 2020, 26, .	0.4	2
930	Clinicopathological and Prognostic Factors in 106 Prostate Cancer Patients Aged ≥55 Years: A Single-Center Study in China. Medical Science Monitor, 2016, 22, 3935-3942.	1.1	5

#	ARTICLE	IF	CITATIONS
931	Baculoviral IAP Repeat Containing 6 (BIRC6) Is a Predictor of Prognosis in Prostate Cancer. Medical Science Monitor, 2018, 24, 839-845.	1.1	12
932	Upregulation of CXCR7 Is Associated with Poor Prognosis of Prostate Cancer. Medical Science Monitor, 2018, 24, 5185-5191.	1.1	11
933	C10orf116 Gene Copy Number Loss in Prostate Cancer: Clinicopathological Correlations and Prognostic Significance. Medical Science Monitor, 2017, 23, 5176-5183.	1.1	7
934	Role of Surgery for locally advanced prostate cancer. Pakistan Journal of Medical Sciences, 1969, 31, 710-6.	0.6	10
935	Phospho-Akt Immunoreactivity in Prostate Cancer: Relationship to Disease Severity and Outcome, Ki67 and Phosphorylated EGFR Expression. PLoS ONE, 2012, 7, e47994.	2.5	31
936	WISP1/CCN4: A Potential Target for Inhibiting Prostate Cancer Growth and Spread to Bone. PLoS ONE, 2013, 8, e71709.	2.5	64
937	Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0–10.0 ng/ml. PLoS ONE, 2015, 10, e0130308.	2.5	14
938	Residential Exposure to Road and Railway Noise and Risk of Prostate Cancer: A Prospective Cohort Study. PLoS ONE, 2015, 10, e0135407.	2.5	8
939	Association between Seminal Vesicle Invasion and Prostate Cancer Detection Location after Transrectal Systemic Biopsy among Men Who Underwent Radical Prostatectomy. PLoS ONE, 2016, 11, e0148690.	2.5	4
940	Evaluating Prostate Cancer Using Fractional Tissue Composition of Radical Prostatectomy Specimens and Pre-Operative Diffusional Kurtosis Magnetic Resonance Imaging. PLoS ONE, 2016, 11, e0159652.	2.5	24
941	CD147 and Prostate Cancer: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0163678.	2.5	13
942	Determining the optimal number and location of cutoff points with application to data of cervical cancer. PLoS ONE, 2017, 12, e0176231.	2.5	33
943	Expression of ribosomal proteins in normal and cancerous human prostate tissue. PLoS ONE, 2017, 12, e0186047.	2.5	58
944	Evolving Recommendations on Prostate Cancer Screening. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e80-e87.	3.8	6
945	Prostate Cancer Screening in BRCA and Lynch Syndrome Mutation Carriers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e50-e55.	3.8	7
946	Chromatin reprogramming as an adaptation mechanism in advanced prostate cancer. Endocrine-Related Cancer, 2019, 26, R211-R235.	3.1	15
947	Does Obesity Impact Treatment Outcome for Prostate Cancer Patients Treated with Radiotherapy: The Weighted Debate. Journal of Cancer Prevention & Current Research, 2014, 1, .	0.1	2
948	Active surveillance in intermediate risk prostate cancer: is it safe?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2016, 42, 413-417.	1.5	2

#	ARTICLE	IF	CITATIONS
949	Efficacy of Leuporelde acetate (Eligard®) in daily practice in Brazil: a retrospective study with depot formulations in patients with prostate cancer. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2020, 46, 383-389.	1.5	8
950	Diagnosis accuracy of PCA3 level in patients with prostate cancer: a systematic review with meta-analysis. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2020, 46, 691-704.	1.5	9
951	Risk of Prostate Cancer Incidence among Atomic Bomb Survivors: 1958–2009. Radiation Research, 2020, 195, 66-76.	1.5	15
952	Clinical significance of PSA-associated tests in the diagnosis and staging of prostate cancer. Onkologiya Zhurnal Imeni P A Gertsena, 2018, 7, 55.	0.2	6
953	Mortality Rate and Years of Life Lost Due to Prostate Cancer in Yazd Province, Iran: A 10-year study. Sultan Qaboos University Medical Journal, 2018, 17, 424.	1.0	6
954	Topoisomerase II-binding protein 1 promotes the progression of prostate cancer via ATR-CHK1 signaling pathway. Aging, 2020, 12, 9948-9958.	3.1	6
955	The PI3K regulatory subunit gene PIK3R1 is under direct control of androgens and repressed in prostate cancer cells. Oncoscience, 2015, 2, 755-764.	2.2	23
956	Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget, 2016, 7, 64447-64470.	1.8	130
957	Correlation between body mass index (BMI) and the Gleason score of prostate biopsies in Chinese population. Oncotarget, 2016, 7, 63338-63341.	1.8	3
958	Androgen receptor phosphorylation status at serine 578 predicts poor outcome in prostate cancer patients. Oncotarget, 2017, 8, 4875-4887.	1.8	14
959	Probing the prostate tumour microenvironment I: impact of glucose deprivation on a cell model of prostate cancer progression. Oncotarget, 2017, 8, 14374-14394.	1.8	7
960	Impact of DNA repair gene polymorphisms on the risk of biochemical recurrence after radiotherapy and overall survival in prostate cancer. Oncotarget, 2017, 8, 22863-22875.	1.8	9
961	Characteristics of prostate cancer detection rate (PCDR) in Chinese Han population under different prostate biopsy methods. Oncotarget, 2017, 8, 32930-32936.	1.8	4
962	The combination of prostate imaging reporting and data system version 2 (PI-RADS v2) and periprostatic fat thickness on multi-parametric MRI to predict the presence of prostate cancer. Oncotarget, 2017, 8, 44040-44049.	1.8	15
963	Network meta-analysis of the efficacy and adverse effects of several treatments for advanced/metastatic prostate cancer. Oncotarget, 2017, 8, 59709-59719.	1.8	6
964	High expression of PDLIM5 facilitates cell tumorigenesis and migration by maintaining AMPK activation in prostate cancer. Oncotarget, 2017, 8, 98117-98134.	1.8	21
965	Identification of SPOP related metabolic pathways in prostate cancer. Oncotarget, 2017, 8, 103032-103046.	1.8	16
966	Integrated analysis of epigenomic and genomic changes by DNA methylation dependent mechanisms provides potential novel biomarkers for prostate cancer. Oncotarget, 2014, 5, 7858-7869.	1.8	17



#	ARTICLE	IF	CITATIONS
967	DAPK and CIP2A are involved in GAS6/AXL-mediated Schwann cell proliferation in a rat model of bilateral cavernous nerve injury. <i>Oncotarget</i> , 2018, 9, 6402-6415.	1.8	3
968	Testosterone metabolites inhibit proliferation of castration- and therapy-resistant prostate cancer. <i>Oncotarget</i> , 2018, 9, 16951-16961.	1.8	10
969	Mitochondrial oncobioenergetic index: A potential biomarker to predict progression from indolent to aggressive prostate cancer. <i>Oncotarget</i> , 2015, 6, 43065-43080.	1.8	24
970	A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population. <i>Oncotarget</i> , 2016, 7, 21393-21403.	1.8	18
971	G protein-coupled receptor GPR160 is associated with apoptosis and cell cycle arrest of prostate cancer cells. <i>Oncotarget</i> , 2016, 7, 12823-12839.	1.8	24
972	Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer. <i>Oncotarget</i> , 2016, 7, 69397-69411.	1.8	17
973	Prediction of <i>mycoplasma hominis</i> proteins targeting in mitochondria and cytoplasm of host cells and their implication in prostate cancer etiology. <i>Oncotarget</i> , 2017, 8, 30830-30843.	1.8	36
974	Monitoring Quality of Care in Men Diagnosed with Prostate Cancer: Developing Consensus Quality Indicators Using Modified-Delphi Methodology. <i>Journal of Epidemiology and Preventive Medicine</i> , 2015, 1, .	0.2	1
975	Serum biomarkers of inflammation for diagnosis of prostate cancer in patients with nonspecific elevations of serum prostate specific antigen levels. <i>Translational Cancer Research</i> , 2019, 8, 273-278.	1.0	5
976	Adjuvant hormone therapy after radical prostatectomy in high-risk localized and locally advanced prostate cancer: First multicenter, observational study in China. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 511-520.	2.2	7
977	Incidencia, mortalidad y supervivencia al c�ncer de pr�stata en Cali, Colombia, 1962-2011. <i>Salud Publica De Mexico</i> , 2014, 56, 440.	0.4	14
978	Incidencia, mortalidad y supervivencia por c�ncer colorrectal en Cali, Colombia, 1962-2012. <i>Salud Publica De Mexico</i> , 2014, 56, 457.	0.4	9
979	The burden of cancer in Mexico, 1990-2013. <i>Salud Publica De Mexico</i> , 2016, 58, 118-131.	0.4	38
980	&lt;p&gt;Long Non-Coding RNA GAS5 Suppresses Tumor Progression and Enhances the Radiosensitivity of Prostate Cancer Through the miR-320a/RAB21 Axis&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 8833-8845.	1.9	14
981	Adiponectin as a Potential Therapeutic Target for Prostate Cancer. <i>Current Pharmaceutical Design</i> , 2017, 23, 4170-4179.	1.9	27
982	The Relationship Between Prostate Cancer and Metformin Consumption: A Systematic Review and Meta-analysis Study. <i>Current Pharmaceutical Design</i> , 2019, 25, 1021-1029.	1.9	12
983	Detection of Local Recurrence with 3-Tesla MRI After Radical Prostatectomy: A Useful Method for Radiation Treatment Planning?. <i>In Vivo</i> , 2018, 32, 125-131.	1.3	7
984	GSTM1 and GSTT1 Polymorphisms and Susceptibility to Prostate Cancer: A Case-Control Study of the Algerian Population. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 2853-2858.	1.2	10



#	ARTICLE	IF	CITATIONS
985	Prostate-specific membrane antigen radioligand therapy of prostate cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 29-36.	0.7	8
986	Cancer survival in Cali, Colombia: A population-based study, 1995-2004. Colombia Medica, 2014, , 110-116.	0.2	19
987	A molecule inducing androgen receptor degradation and selectively targeting prostate cancer cells. Life Science Alliance, 2019, 2, e201800213.	2.8	12
988	Association of CYP1A1 rs1048943 Polymorphism with Prostate Cancer in Iraqi Men Patients. Asian Pacific Journal of Cancer Prevention, 2019, 20, 3839-3842.	1.2	10
989	Dietary Nutrient Patterns and Prostate Cancer Risk: A Case-Control Study from Iran. Asian Pacific Journal of Cancer Prevention, 2019, 20, 1415-1420.	1.2	3
990	Diagnostic performance of a nomogram incorporating cribriform morphology for the prediction of adverse pathology in prostate cancer at radical prostatectomy. Oncology Letters, 2020, 20, 2797-2805.	1.8	4
991	Intracellular calcium excess as one of the main factors in the etiology of prostate cancer. AIMS Molecular Science, 2016, 3, 635-647.	0.5	16
992	Molecular aspects of prostate cancer with neuroendocrine differentiation. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 122-9.	2.2	14
993	Demography and disease characteristics of prostate cancer in India. Indian Journal of Urology, 2016, 32, 103.	0.6	58
994	Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer. Indian Journal of Urology, 2016, 32, 257.	0.6	7
995	Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian Journal of Andrology, 2014, 16, 387.	1.6	43
996	Genetic variations of the ADIPOQ gene and risk of prostate cancer in Chinese Han men. Asian Journal of Andrology, 2014, 16, 878.	1.6	15
997	Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml <sup>-1</sup> . Asian Journal of Andrology, 2015, 17, 1017.	1.6	9
998	Prostate cancer antigen 3 moderately improves diagnostic accuracy in Chinese patients undergoing first prostate biopsy. Asian Journal of Andrology, 2017, 19, 238.	1.6	19
999	Mutation of MED12 is not a frequent occurrence in prostate cancer of Korean patients. Asian Journal of Andrology, 2017, 19, 346.	1.6	4
1000	Prevalence and clinical application of TMPRSS2-ERG fusion in Asian prostate cancer patients: a large-sample study in Chinese people and a systematic review. Asian Journal of Andrology, 2020, 22, 200.	1.6	14
1001	Phosphoglycerate mutase 1 knockdown inhibits prostate cancer cell growth, migration, and invasion. Asian Journal of Andrology, 2018, 20, 178.	1.6	18
1002	Contemporary trends in radical prostatectomy and predictors of recovery of urinary continence in men aged over 70 years: comparisons between cohorts aged over 70 and less than 70 years. Asian Journal of Andrology, 2020, 22, 280.	1.6	9

#	ARTICLE	IF	CITATIONS
1003	Transrectal ultrasound-guided prostate rebiopsy: How many core sampling should be applied to which patient?. Urology Annals, 2018, 10, 15.	0.6	1
1004	Incidence of metastasis and prostate-specific antigen levels at diagnosis in Gleason 3+4 versus 4+3 prostate cancer. Urology Annals, 2018, 10, 203.	0.6	14
1005	Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years. World Journal of Nuclear Medicine, 2020, 19, 15-20.	0.5	17
1006	Time Trends for Prostate Cancer Incidence from 2003 to 2013 in South Korea: An Age-Period-Cohort Analysis. Cancer Research and Treatment, 2020, 52, 301-308.	3.0	9
1007	Patient-Reported Outcomes in Prostate Cancer: Prospective Changes Analysis for Prognosis Prediction. Journal of Cancer Therapy, 2015, 06, 1238-1248.	0.4	3
1008	Knowledge, Health Beliefs and Screening Status of Prostate Cancer among Middle-Aged and Elderly Men. Open Journal of Nursing, 2016, 06, 672-687.	0.4	7
1009	Comparison of Single and Prolonged Fluoroquinolone Prophylaxis and Risk Factors for Infectious Complications After Transrectal Prostate Biopsy. Balkan Medical Journal, 2018, 35, 373-377.	0.8	6
1010	Value of prostate-specific antigen density in negative or equivocal lesions on multiparametric magnetic resonance imaging. Turkish Journal of Urology, 2020, 46, 367-372.	1.3	8
1011	Transrectal-ultrasound prostatic biopsy preparati rectal enema vs. mechanical bowel preparation. Central European Journal of Urology, 2015, 68, 223-8.	0.3	10
1012	Intracellular Zinc Excess as One of the Main Factors in the Etiology of Prostate Cancer. Journal of Analytical Oncology, 2016, 5, 124-131.	0.1	17
1013	Korean Prostate Cancer Patients Have Worse Disease Characteristics than their American Counterparts. Asian Pacific Journal of Cancer Prevention, 2013, 14, 6913-6917.	1.2	30
1014	Cancer Incidence in Southwest of Iran: First Report from Khuzestan Population-Based Cancer Registry, 2002-2009. Asian Pacific Journal of Cancer Prevention, 2013, 14, 7517-7522.	1.2	50
1015	Correlation between Low Gleason Score and Prostate Specific Antigen Levels with Incidence of Bone Metastases in Prostate Cancer Patients: When to Omit Bone Scans?. Asian Pacific Journal of Cancer Prevention, 2013, 14, 4973-4976.	1.2	15
1016	Fruit and Vegetable Intake in Relation to Prostate Cancer in Iranian Men: A Case-Control Study. Asian Pacific Journal of Cancer Prevention, 2014, 15, 5223-5227.	1.2	33
1017	Epidemiology and Prevention of Prostate Cancer in Vietnam. Asian Pacific Journal of Cancer Prevention, 2014, 15, 9747-9751.	1.2	16
1018	Significant Association of Metabolic Indices, Lipid Profile, and Androgen Levels with Prostate Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 9841-9846.	1.2	11
1019	Evaluation of Environmental Risk Factors for Prostate Cancer in a Population of Iranian Patients. Asian Pacific Journal of Cancer Prevention, 2015, 15, 10603-10605.	1.2	9
1020	Up-regulating of RASD1 and Apoptosis of DU-145 Human Prostate Cancer Cells Induced by Formononetin in Vitro. Asian Pacific Journal of Cancer Prevention, 2014, 15, 2835-2839.	1.2	30

#	ARTICLE	IF	CITATIONS
1021	Epidemiology of Prostate Cancer. Asian Pacific Journal of Cancer Prevention, 2015, 16, 5137-5141.	1.2	131
1022	Androgen-regulated transcription of ESRP2 drives alternative splicing patterns in prostate cancer. ELife, 2019, 8, .	6.0	56
1023	A pilot study to investigate if New Zealand men with prostate cancer benefit from a Mediterranean-style diet. PeerJ, 2015, 3, e1080.	2.0	22
1024	Role of methyltransferase-like enzyme 3 and methyltransferase-like enzyme 14 in urological cancers. PeerJ, 2020, 8, e9589.	2.0	17
1025	Prostate Cancer Incidence in Calabar - Nigeria. British Journal of Medicine and Medical Research, 2016, 14, 1-10.	0.2	1
1026	Comprehensive Characterization of Androgen-Responsive circRNAs in Prostate Cancer. Life, 2021, 11, 1096.	2.4	3
1027	Hsa_circ_0004296 inhibits metastasis of prostate cancer by interacting with EIF4A3 to prevent nuclear export of ETS1 mRNA. Journal of Experimental and Clinical Cancer Research, 2021, 40, 336.	8.6	23
1028	Can machine learning-based analysis of multiparameter MRI and clinical parameters improve the performance of clinically significant prostate cancer diagnosis?. International Journal of Computer Assisted Radiology and Surgery, 2021, 16, 2235-2249.	2.8	12
1029	Ethnic and regional differences in the temporal trends of prostate cancer incidence and mortality in New Zealand. ANZ Journal of Surgery, 2021, , .	0.7	0
1030	Circular RNAs in prostate cancer: Biogenesis, biological functions, and clinical significance. Molecular Therapy - Nucleic Acids, 2021, 26, 1130-1147.	5.1	19
1031	Update on Diagnostic Criteria, on Biopsy and Surgical Specimen: Preinvasive Lesions, from Epithelial Cell Hyperplasia to Carcinoma In Situ and Invasive Carcinoma – First-Line Immuno-Phenotyping of Prostate Diseases. , 2013, , 3-42.		0
1032	If Nature Failed Creating the Perfect Prostate Could Inhibitors of Proteolysis Help?. , 2013, 02, .		0
1033	The role of prostate-specific antigen (PSA) testing in screening for prostate cancer. University of Western Ontario Medical Journal, 2013, 82, 17-18.	0.1	1
1034	Gamete/Embryo-Fetal Origins of Tumours. , 2014, , 109-136.		0
1035	The role of surgery as active treatment for high risk localized prostate cancer seen from an epidemiological perspective. OA Epidemiology, 2013, 1, .	0.2	0
1036	Introduction to Prostate Cancer. , 2014, , 553-557.		0
1037	Second-line chemotherapy in castration-resistant prostate cancer. Onkologiya Zhurnal Imeni P A Gertsena, 2014, 3, 37.	0.2	0
1038	EpidemiologÃa del cÃncer de prÃstata. , 2014, , 1-3.		0

#	ARTICLE	IF	CITATIONS
1039	Radical Prostatectomy in the Robotic Era. Comparison of Three Different Methods: Retropubic, Robotic and Perineal. Journal of Urological Surgery, 2014, 1, 1-10.	0.1	1
1040	Incidental detection of prostate-specific antigen-negative metastatic prostate cancer initially presented with solitary pulmonary nodule on fluorodeoxyglucose positron emission tomography/computed tomography. Indian Journal of Nuclear Medicine, 2015, 30, 268.	0.3	1
1043	Prostatakarzinom: Epidemiologie, Ätiologie, Prävention und Früherkennung/Screening. , 2015, , 1-6.		0
1045	Obesity and Cancer: What's the Interconnection?. Advances in Obesity Weight Management & Control, 2015, 2, .	0.2	0
1046	Prostatic adenocarcinoma with initial metastatic spread to the mandible. Turkish Journal of Urology, 2015, 41, 149-151.	1.3	2
1047	Depression Risk and Cancer in Ecuador: The Protective Role of Social Support. Mental Health in Family Medicine, 2015, 11, .	0.2	0
1048	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2016, , 1-41.		0
1049	Decision Support for Low-Risk Prostate Cancer. , 2016, , 207-213.		1
1050	Long-Term Oncologic Outcomes of Robot-Assisted Radical Prostatectomy. , 2016, , 281-286.		0
1051	Apex: The Crossroads of Functional Recovery and Oncologic Control. , 2016, , 99-104.		0
1052	Prostatakarzinom: Epidemiologie, Ätiologie, Prävention und Früherkennung/Screening. , 2016, , 1301-1304.		0
1053	Active surveillance of patients with prostate cancer (Literature review). Health of Man, 2016, .	0.0	0
1054	Combinations of Hormonal Therapy and Chemotherapy. , 2017, , 135-146.		0
1055	Penile Metastasis Originating from Prostate Adenocarcinoma: An Unusual Presentation with Penile Curvature. Nephro-Urology Monthly, 2016, 9, .	0.1	1
1056	Chapter 2 Global Epidemiology of Prostate Cancer. Traditional Herbal Medicines for Modern Times, 2016, , 17-28.	0.1	0
1057	Twenty-Year Single Surgeon Experience with Radical Perineal Prostatectomy: Oncologic, Functional Outcomes and Perioperative Complications. The Korean Journal of Urological Oncology, 2016, 14, 144-151.	0.1	2
1058	CAN LEVELS OF URINARY MATRIX METALLOPROTEINASES (MMPS) ACT AS AN ALTERNATIVE TO GLEASON'S SCORING IN PROSTATIC MALIGNANCIES. Journal of Evolution of Medical and Dental Sciences, 2017, 6, 1281-1285.	0.1	0
1059	Complications of miniinvasive radical prostatectomy in patients with localized prostate cancer. Health of Man, 2017, .	0.0	1

#	ARTICLE	IF	CITATIONS
1060	<i>Biophytum sensitivum</i> nanomedicine reduces cell viability and nitrite production in prostate cancer cells. IET Nanobiotechnology, 2017, 11, 782-789.	3.8	0
1061	Epidemiology, Energy Balance and Prostate Cancer Incidence and Mortality. Energy Balance and Cancer, 2018, , 1-20.	0.2	0
1062	Epidemiology and Etiology. Molecular Pathology Library, 2018, , 13-26.	0.1	0
1063	Effect of <i>Levisticum officinale</i> Hydroalcoholic Extract on DU-145 and PC-3 Prostate Cancer Cell Lines. Gene, Cell and Tissue, 2017, 4, .	0.2	5
1064	Communicating risk in active surveillance of localised prostate cancer: a protocol for a qualitative study. BMJ Open, 2017, 7, e017372.	1.9	0
1065	Decade-long Trends in Prostate Cancer Incidence and Mortality in Poland, 1999–2012. Polish Annals of Medicine, 0, , .	0.3	1
1066	Effects of a Six-month Supervised Physical Exercise Program on Physical and Cardio-Metabolic Profile and Quality of Life in Patients with Prostate Cancer on Androgen Deprivation Therapy: a Pilot and Feasibility Study.. Central European Journal of Urology, 2018, 71, 234-241.	0.3	1
1068	Rare and challenging two complications after prostate biopsy of an older man. Journal of Surgery and Medicine, 0, , .	0.1	0
1069	THE RATE OF URINARY TRACT INFECTIONS FOLLOWING TRANSRECTAL ULTRASOUND-GUIDED BIOPSY OF PROSTATE IN BABOL, NORTHERN IRAN. Journal of Evolution of Medical and Dental Sciences, 2018, 7, 5390-5393.	0.1	0
1071	Extrascial robot-assisted laparoscopic radical prostatectomy in locally advanced prostate cancer. Minerva Chirurgica, 2019, 74, 78-87.	0.8	3
1072	Robot-assisted extended lymphadenectomy in prostate cancer. Minerva Chirurgica, 2019, 74, 88-96.	0.8	2
1073	Evaluation of various common prostate IMRT techniques based on estimated tumor control and normal tissue complication probabilities in correlation with patients anatomical parameters derived from the CT scans. Polish Journal of Medical Physics and Engineering, 2019, 25, 35-41.	0.6	5
1075	Roboto asistuojamos radikalios prostatektomijos pirminiai rezultatai Klaipėdos universitetinėje ligoninėje: vieno centro patirtis. Lietuvos Chirurgija, 2019, 18, 23-27.	0.0	0
1078	Prostate cancer: an occupational hazard in Romania?. Romanian Journal of Occupational Medicine, 2019, 70, 38-45.	0.1	0
1079	The 10-Year Incidence Trend of Common Cancers at a Referral Hospital in Tehran, Iran From 2007 to 2016. Hospital Practices and Research, 2019, 4, 80-85.	0.2	0
1080	Risk factors of prostate cancer. Medical Almanac, 2019, , 110-114.	0.1	5
1081	A Study on Risk Factors of the Incidence of Prostate Cancer Using National Health Insurance Service: Effects of BMI on Age. Journal of Health Informatics and Statistics, 2019, 44, 410-418.	0.4	1
1082	Lung uptake of fluorine-18 fluoroethyl-choline PET-CT in patients with prostate cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 387-393.	0.7	0

#	ARTICLE	IF	CITATIONS
1083	Wide-field optical spectroscopy system integrating reflectance and spatial frequency domain imaging to measure attenuation-corrected intrinsic tissue fluorescence in radical prostatectomy specimens. Biomedical Optics Express, 2020, 11, 2052.	2.9	4
1084	Evolution of prostate cancer diagnosis: retrospective analysis of magnetic resonance imaging/ultrasound fusion guided biopsies protocol in routine practice and patients management. Translational Andrology and Urology, 2020, 9, 629-636.	1.4	1
1085	Trends in the incidence rate of genitourinary system cancers in Turkey: 2004â€“2015. Turkish Journal of Urology, 2020, 46, 196-205.	1.3	1
1088	Does shared decision making increase prostate screening uptake in countries with a low prevalence of prostate cancer?. African Health Sciences, 2020, 20, 1870-4.	0.7	1
1089	Novel therapeutic compounds for prostate adenocarcinoma treatment. Medicine (United States), 2020, 99, e23768.	1.0	2
1092	Global Burden of Cancer: Prevalence, Pattern, and Trends. , 2020, , 1-36.		0
1093	Prostatokarzinom: Epidemiologie und Risikofaktoren. Springer Reference Medizin, 2020, , 1-21.	0.0	0
1094	Epidemiology of Prostate Cancer in the Republic of Kazakhstan. Iranian Journal of Public Health, 0, , .	0.5	2
1095	Ege Üniversitesi hastanesinde prostat kanserlerinin epidemiyolojisi ve genel saĖkalÄ±m Ä¶zellikleri. Ege TÄ±p Dergisi, 0, 59, 33-39.	0.2	0
1097	The PSA tracker: a computerised health care system initiative in Northern Ireland. Ulster Medical Journal, 2013, 82, 146-9.	0.2	5
1098	The relevance of the procedures related to the physiotherapy in the interventions in patients with prostate cancer: short review with practice approach. International Journal of Biomedical Science, 2014, 10, 73-84.	0.1	3
1099	Cancer survival in Cali, Colombia: A population-based study, 1995-2004. Colombia Medica, 2014, 45, 110-6.	0.2	11
1100	LKB1 suppresses proliferation and invasion of prostate cancer through hedgehog signaling pathway. International Journal of Clinical and Experimental Pathology, 2014, 7, 8480-8.	0.5	12
1101	Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis. Ontario Health Technology Assessment Series, 2015, 15, 1-64.	1.8	20
1102	Metformin therapy and prostate cancer risk: a meta-analysis of observational studies. International Journal of Clinical and Experimental Medicine, 2015, 8, 13089-98.	1.3	11
1103	What Are the Links of Prostate Cancer with Physical Activity and Nutrition? : A Systematic Review Article. Iranian Journal of Public Health, 2016, 45, 1558-1567.	0.5	6
1104	LncRNAs and miRNAs: potential biomarkers and therapeutic targets for prostate cancer. American Journal of Translational Research (discontinued), 2016, 8, 5141-5150.	0.0	36
1105	Synergistic Effects of NDRG2 Overexpression and Radiotherapy on Cell Death of Human Prostate LNCaP Cells. Journal of Biomedical Physics and Engineering, 2017, 7, 257-264.	0.9	4

#	ARTICLE	IF	CITATIONS
1106	MANAGEMENT OF PROSTATE CANCER IN ACCRA, GHANA. Journal of the West African Colleges of Surgeons, 2016, 6, 31-65.	0.2	3
1108	Associations of LIM kinase1 (LIMK1) gene single nucleotide polymorphisms with prostate cancer susceptibility in Chinese population. International Journal of Clinical and Experimental Pathology, 2017, 10, 9725-9734.	0.5	1
1109	Epidemiology of Prostate Cancer in the Republic of Kazakhstan. Iranian Journal of Public Health, 2019, 48, 2216-2223.	0.5	0
1110	Oncoxin-Viusid may improve quality of life and survival in patients with hormone-refractory prostate cancer undergoing onco-specific treatments. Molecular and Clinical Oncology, 2021, 14, 5.	1.0	2
1111	Folic Acid-Modified miR-491-5p-Loaded ZIF-8 Nanoparticles Inhibit Castration-Resistant Prostate Cancer by Regulating the Expression of EPHX1. Frontiers in Bioengineering and Biotechnology, 2021, 9, 706536.	4.1	11
1112	The influence of age on prostate cancer screening index. Journal of Clinical Laboratory Analysis, 2022, 36, e24098.	2.1	6
1113	Effectiveness of cognitive behavioural therapy on quality of life in patients with prostate cancer after androgen deprivation therapy: a protocol for systematic review and meta-analysis. BMJ Open, 2021, 11, e049314.	1.9	1
1114	Comparative Analysis of Robot-Assisted, Laparoscopic, and Open Radical Prostatectomy Regarding Lower Urinary Tract Symptoms. Urological Science, 2020, 31, 21-27.	0.6	3
1115	Evaluating Incidence, Location, and Predictors of Positive Surgical Margin Among Chinese Men Undergoing Robot-Assisted Radical Prostatectomy. Cancer Control, 2021, 28, 107327482110552.	1.8	2
1116	Trends in Prostate Specific Antigen (PSA) testing and prostate cancer incidence and mortality in Australia: A critical analysis. Cancer Epidemiology, 2022, 77, 102093.	1.9	13
1117	Oncoxin-Viusid<sup>®</sup> may improve quality of life and survival in patients with hormone-refractory prostate cancer undergoing onco-specific treatments. Molecular and Clinical Oncology, 2020, 14, 1-1.	1.0	3
1118	Prostate cancer and human papillomavirus infection. Reviews in Medical Microbiology, 2020, Publish Ahead of Print, .	0.9	2
1119	A critical analysis of deficiencies in the quality of information contained in prostate multiparametric MRI requests and reports. Irish Journal of Medical Science, 2022, , 1.	1.5	1
1120	Different Trends in the Incidence and Mortality Rates of Prostate Cancer Between China and the USA: A Joinpoint and Age-Period-Cohort Analysis. Frontiers in Medicine, 2022, 9, 824464.	2.6	11
1121	Cancer Statistics over Time in Northwestern São Paulo State, Brazil: Incidence and Mortality. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 707-714.	2.5	2
1122	Alterations of Plasma Exosomal Proteins and Metabolites are Associated with the Progression of Castration-Resistant Prostate Cancer. SSRN Electronic Journal, 0, , .	0.4	0
1123	Long non-coding RNA PRNCR1 promotes ovarian cancer cell proliferation, migration and invasion by targeting the miR-653-5p/ELF2 axis. Molecular and Cellular Biochemistry, 2022, 477, 1463-1475.	3.1	6
1124	The modified prostate health index (PHI) outperforms PHI density in the detection of clinical prostate cancer within the PSA grey zone. International Urology and Nephrology, 2022, 54, 749-756.	1.4	5



#	ARTICLE	IF	CITATIONS
1125	The effects of exercise on body composition of prostate cancer patients receiving androgen deprivation therapy: An update systematic review and meta-analysis. PLoS ONE, 2022, 17, e0263918.	2.5	8
1126	mCRPC Patients Receiving <sup>225</sup> Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis. Journal of Nuclear Medicine, 2022, 63, 1496-1502.	5.0	20
1127	The Classification Power of Classical and Intra-voxel Incoherent Motion (IVIM) Fitting Models of Diffusion-weighted Magnetic Resonance Images: An Experimental Study. Journal of Digital Imaging, 2022, 35, 678-691.	2.9	2
1128	Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019. Frontiers in Public Health, 2022, 10, 811044.	2.7	171
1129	Calreticulin Regulates $\beta$ 2-Integrin mRNA Stability in PC-3 Prostate Cancer Cells. Biomedicines, 2022, 10, 646.	3.2	1
1130	Apaf-1 interacting protein, a new target of microRNA-146a-3p, promotes prostate cancer cell development via the ERK1/2 pathway. Cell Biology International, 2022, 46, 1156-1168.	3.0	3
1131	Construction of Bone Metastasis-Specific Regulation Network Based on Prognostic Stemness-Related Signatures in Prostate Cancer. Disease Markers, 2022, 2022, 1-27.	1.3	2
1132	Do all patients with suspicious prostate cancer need Multiparametric Magnetic Resonance Imaging before prostate biopsy?. Archivio Italiano Di Urologia Andrologia, 2022, 94, 32-36.	0.8	1
1133	Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. European Urology, 2022, 82, 341-351.	1.9	32
1134	Modified Prostate Health Index Density Significantly Improves Clinically Significant Prostate Cancer (csPCa) Detection. Frontiers in Oncology, 2022, 12, 864111.	2.8	4
1135	Identification of Potential Key Genes in Prostate Cancer with Gene Expression, Pivotal Pathways and Regulatory Networks Analysis Using Integrated Bioinformatics Methods. Genes, 2022, 13, 655.	2.4	10
1136	Raloxifene Suppresses Tumor Growth and Metastasis in an Orthotopic Model of Castration-Resistant Prostate Cancer. Biomedicines, 2022, 10, 853.	3.2	0
1137	Prophylactic role of ciprofloxacin and ceftriaxone in prostate biopsy-related infection: randomized comparative study of bacterial spectrum and antibiotic sensitivities. African Journal of Urology, 2021, 27, .	0.4	1
1138	Metabolic syndrome and prostate cancer in Afro-Caribbean men. Prostate, 2022, 82, 359-365.	2.3	3
1139	Implications and relative importance of GSTP1, GSTM1 and GSTT1 Polymorphisms in the prevalence and severity of prostate cancer in an Eastern Indian Population. Medical Journal of Dr D Y Patil Vidyapeeth, 2022, .	0.1	0
1140	Dihydrochalcones as Antitumor Agents. Current Medicinal Chemistry, 2022, 29, 5042-5061.	2.4	1
1141	Developments in proton MR spectroscopic imaging of prostate cancer. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2022, 35, 645-665.	2.0	6
1150	Investigation of Tumor Cells and Receptor-Ligand Simulation Models for the Development of PET Imaging Probes Targeting PSMA and GRPR and a Possible Crosstalk between the Two Receptors. Molecular Pharmaceutics, 2022, 19, 2231-2247.	4.6	5

#	ARTICLE	IF	CITATIONS
1151	Epidemiology of Prostate Cancer in Croatia - Situation and Perspectives. Acta Clinica Croatica, 2018, 57, 27-34.	0.2	3
1153	Prevalence, Grades and Management of Prostate Cancer among Men Attending Oncology Unit at Bugando Medical Centre Mwanza, Tanzania. Open Journal of Epidemiology, 2022, 12, 146-157.	0.4	0
1155	Health-seeking Behaviours and Effect of Prostate Cancer on Male Soldiers in Ghana: A Qualitative Study. , 0, , .		0
1156	Prostate Cancer Patterns and Trends in the Eastern Cape Province of South Africa; 1998â€“2017. Frontiers in Public Health, 2022, 10, 882586.	2.7	4
1157	Estimation of utility weights for prostate-related health states in Korea. Journal of Preventive Medicine and Public Health, 0, , .	1.9	0
1158	Comparison of the clinicopathologic features of prostate cancer in US and Chinese populations. Pathology Research and Practice, 2022, 234, 153933.	2.3	0
1159	Socioeconomic differences in prostate cancer treatment: A systematic review and meta-analysis. Cancer Epidemiology, 2022, 79, 102164.	1.9	2
1160	Metronomic Chemotherapy for Advanced Prostate Cancer: A Literature Review. Journal of Clinical Medicine, 2022, 11, 2783.	2.4	6
1161	Conducta sexual y otros factores de riesgo para c�ncer de pr�stata. Revista Mexicana De Urologia, 2019, 79, 1-14.	0.0	4
1162	Prevalence, Grades and Management of Prostate Cancer among Men Attending Oncology Unit at Bugando Medical Centre Mwanza, Tanzania. Open Journal of Epidemiology, 2022, 12, 146-157.	0.4	0
1163	The Association Between Metabolic Syndrome and Prostate Cancer Risk: A Large-Scale Investigation and Study of Chinese. Frontiers in Endocrinology, 2022, 13, .	3.5	1
1164	The Risk for Prostate Cancer With Calcium Channel Blockers: A Systematic Review, Meta-Analysis, and Meta-Regression. Annals of Pharmacotherapy, 2023, 57, 16-28.	1.9	4
1165	Cell-free DNA as a Promising Diagnostic Biomarker in Prostate Cancer: A Systematic Review and Meta-Analysis. Journal of Oncology, 2022, 2022, 1-13.	1.3	2
1167	Automatic prostate and peri-prostatic fat segmentation based on pyramid mechanism fusion network for T2-weighted MRI. Computer Methods and Programs in Biomedicine, 2022, 223, 106918.	4.7	5
1168	Incidence, Mortality, and Trends of Prostate Cancer in Mexico from 2000 to 2019: Results from the Global Burden of Disease Study 2019. Cancers, 2022, 14, 3184.	3.7	2
1169	The Role of Nutrition in the Etiology and Treatment of Prostate Cancer. G�m�hane �niversitesi Sa�ġġ Bilimleri Dergisi, 0, , .	0.4	0
1170	The impact of hegemonic masculine ideals on self�esteem in prostate cancer patients undergoing androgen deprivation therapy (ADT) compared to ADT�na�ve patients. Psycho-Oncology, 2022, 31, 1958-1971.	2.3	5
1171	EXTL3 could serve as a potential biomarker of prognosis and immunotherapy for prostate cancer and its potential mechanisms. European Journal of Medical Research, 2022, 27, .	2.2	6

#	ARTICLE	IF	CITATIONS
1172	Long non-coding RNA PART1: dual role in cancer. Human Cell, 2022, 35, 1364-1374.	2.7	6
1173	The Role of PSMA PET/CT in the Primary Diagnosis and Follow-Up of Prostate Cancer”A Practical Clinical Review. Cancers, 2022, 14, 3638.	3.7	13
1174	Should Contemporary Western Guidelines Based on Studies Conducted in the 2000s Be Adopted for the Prostate-Specific Antigen Screening Policy for Asian Men in the 2020s?. World Journal of Men's Health, 2022, 40, 543.	3.3	4
1176	The implication of molecular markers in the early stage diagnosis of colorectal cancers and precancerous lesions. Biyokimya Dergisi, 2022, 47, 691-703.	0.5	0
1177	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2022, , 1-55.		0
1178	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2022, , 1023-1075.		0
1179	Blood circulating exosomes carrying microRNA-423-5p regulates cell progression in prostate cancer via targeting FRMD3. Journal of Cancer, 2022, 13, 2970-2981.	2.5	2
1180	Comparative Study of Bisacodyl Suppository Plus Antibiotics versus Antibiotics Alone in the Prevention of Postprostate Biopsy Infection. Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria, 2022, 31, 374.	0.1	0
1181	Ductal prostate cancer: Clinical features and outcomes from a multicenter retrospective analysis and overview of the current literature. Current Urology, 2022, 16, 218-226.	0.6	3
1182	An analysis of time trends in breast and prostate cancer mortality rates in Lithuania, 1986–2020. BMC Public Health, 2022, 22, .	2.9	1
1183	Testing the generalizability of ancestry-specific polygenic risk scores to predict prostate cancer in sub-Saharan Africa. Genome Biology, 2022, 23, .	8.8	16
1184	Proteomics reveals MRPL4 as a high-risk factor and a potential diagnostic biomarker for prostate cancer. Proteomics, 2022, 22, .	2.2	2
1185	The influence of prostate volume on clinical parameters in prostate cancer screening. Journal of Clinical Laboratory Analysis, 0, , .	2.1	4
1186	Large-Scale Proteomics Data Reveal Integrated Prognosis-Related Protein Signatures and Role of SMAD4 and RAD50 in Prognosis and Immune Infiltrations of Prostate Cancer Microenvironment. Phenomics, 2022, 2, 404-418.	2.9	14
1187	Identification of the Regulatory Targets of miR-3687 and miR-4417 in Prostate Cancer Cells Using a Proteomics Approach. International Journal of Molecular Sciences, 2022, 23, 10565.	4.1	3
1188	Prostate cancer treatment – China's perspective. Cancer Letters, 2022, 550, 215927.	7.2	24
1189	177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer: A Mini-Review of State-of-the-Art. Oncologist, 2022, 27, e957-e966.	3.7	3
1190	Single-cell RNA-sequencing technology demonstrates the heterogeneity between aged prostate peripheral and transitional zone. Clinical and Translational Medicine, 2022, 12, .	4.0	5

#	ARTICLE	IF	CITATIONS
1191	Clinical photoacoustic/ultrasound dual-modal imaging: Current status and future trends. <i>Frontiers in Physiology</i> , 0, 13, .	2.8	8
1193	Peripheral blood lymphocyte subsets are associated with the clinical outcomes of prostate cancer patients. <i>International Immunopharmacology</i> , 2022, 113, 109287.	3.8	6
1194	Combining prostate health index and multiparametric magnetic resonance imaging may better predict extraprostatic extension after radical prostatectomy. <i>Journal of the Chinese Medical Association</i> , 2023, 86, 52-56.	1.4	5
1195	Guidelines on Management of Prostate Cancer. <i>Annals of the Academy of Medicine, Singapore</i> , 2013, 42, 190-199.	0.4	9
1196	Clinical Issues for Prostate-Specific Antigen Screening: A Narrative Review. <i>European Medical Journal Oncology</i> , 0, , 102-108.	0.0	0
1197	Overexpression of Estrogen Receptor 1 (ESR-1) in metastatic prostate cancer. <i>Indonesia Journal of Biomedical Science</i> , 2022, 16, 47-50.	0.0	0
1198	Traditional Korean Medicine Treatment for Sequelae After Surgery in Prostate Cancer Patients: Two Case Report. <i>The Journal of Internal Korean Medicine</i> , 2022, 43, 795-808.	0.3	0
1199	Papel do enfermeiro atuante na estratégia saãde da família na prevenção do cânc̃er de prãstata. <i>Research, Society and Development</i> , 2022, 11, e09111637898.	0.1	0
1200	PRState: Incorporating genetic ancestry in prostate cancer risk scores for men of African ancestry. <i>BMC Cancer</i> , 2022, 22, .	2.6	0
1201	Surgical Treatment of the Five Most Common Types of Cancer in Brazil: 7 Years Analysis Overview. <i>American Surgeon</i> , 2023, 89, 578-582.	0.8	2
1202	Mendelian randomization analyses identified bioavailable testosterone mediates the effect of sex hormoneâ€binding globulin on prostate cancer. <i>Andrology</i> , 2023, 11, 1023-1030.	3.5	2
1203	Trends in prostate cancer mortality in the United States of America, by state and race, from 1999 to 2019: estimates from the centers for disease control WONDER database. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 552-562.	3.9	2
1204	Is there any effect of long term alpha-adrenergic blocker and a single dose antibiotic usage in reducing febrile urinary tract infections after prostate biopsy?. <i>Journal of Health Sciences and Medicine</i> , 2023, 6, 1-6.	0.1	0
1205	Mechanistic Investigation of the Androgen Receptor DNA-Binding Domain and Modulation via Direct Interactions with DNA Abasic Sites: Understanding the Mechanisms Involved in Castration-Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1270.	4.1	3
1206	Penile metastasis from prostate cancer misdiagnosed as Peyronie disease: a case report. <i>Sexual Medicine</i> , 2023, 11, .	1.6	1
1207	Potential plasma microRNAs signature miR-190b-5p, miR-215-5p and miR-527 as non-invasive biomarkers for prostate cancer. <i>Biomarkers</i> , 2023, 28, 227-237.	1.9	2
1208	Association of Matrix Metalloproteinase-2 Genotypes With Prostate Cancer Risk. <i>Anticancer Research</i> , 2023, 43, 343-349.	1.1	2
1209	Association of Matrix Metalloproteinase-7 Genotypes With Prostate Cancer Risk. <i>Anticancer Research</i> , 2023, 43, 381-387.	1.1	1

#	ARTICLE	IF	CITATIONS
1210	Association of Haplotypes in Exon 4 of KLK2 Gene with Raised Serum Prostate-Specific Antigen. American Journal of Molecular Biology, 2023, 13, 57-66.	0.3	0
1211	Alterations of plasma exosomal proteins and motabolies are associated with the progression of castration-resistant prostate cancer. Journal of Translational Medicine, 2023, 21, .	4.4	9
1212	Underlying Features of Prostate Cancerâ€™Statistics, Risk Factors, and Emerging Methods for Its Diagnosis. Current Oncology, 2023, 30, 2300-2321.	2.2	14
1213	Biological functions and therapeutic potential of SHCBP1 in human cancer. Biomedicine and Pharmacotherapy, 2023, 160, 114362.	5.6	4
1214	Role of Metabolism and Metabolic Pathways in Prostate Cancer. Metabolites, 2023, 13, 183.	2.9	2
1215	Metastatic bone damage in prostate cancer as a cause of chronic musculoskeletal pain. Clinical Medicine and Pharmacology, 2023, 8, 20-24.	0.1	0
1216	Mass Spectrometry-Based Biomarkers to Detect Prostate Cancer: A Multicentric Study Based on Non-Invasive Urine Collection without Prior Digital Rectal Examination. Cancers, 2023, 15, 1166.	3.7	4
1217	Cancer survival in the northwestern of SÃ£o Paulo State, Brazil: A population-based study. Cancer Epidemiology, 2023, 83, 102339.	1.9	1
1219	Correlations of PTEN and ERG Immunoexpression in Prostate Carcinoma and Lesions Related to Its Natural History: Clinical Perspectives. Current Issues in Molecular Biology, 2023, 45, 2767-2780.	2.4	2
1220	HP1± promotes the progression of prostate cancer. Molecular Biology Reports, 0, , .	2.3	0
1221	Recent advances in analysis technology for detection of prostate cancer biomarkers. Microchemical Journal, 2023, 190, 108740.	4.5	4
1222	Malignant function of nuclear factor-kappaB axis in prostate cancer: Molecular interactions and regulation by non-coding RNAs. Pharmacological Research, 2023, 194, 106775.	7.1	4
1223	Association Between Statin Exposure and Incidence and Prognosis of Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2023, 46, 323-334.	1.3	2
1224	Predictors of Prostate Cancer at Fusion Biopsy: The Role of Positive Family History, Hypertension, Diabetes, and Body Mass Index. Current Oncology, 2023, 30, 4957-4965.	2.2	1
1225	Recent Mortality Patterns and Time Trends for the Major Cancers in 47 Countries Worldwide. Cancer Epidemiology Biomarkers and Prevention, 2023, 32, 894-905.	2.5	7
1226	Trends in estrogen and progesterone receptors in prostate cancer: a bibliometric analysis. Frontiers in Oncology, 0, 13, .	2.8	0
1227	Design and Validation of a Nonparasitic 2R1T Parallel Hand-Held Prostate Biopsy Robot With Remote Center of Motion. Journal of Mechanisms and Robotics, 2024, 16, .	2.2	4
1228	A retrospective study on the incidence, management and risk factors of skin rash in patients with advanced prostate cancer in Japan. BMC Urology, 2023, 23, .	1.4	1

#	ARTICLE	IF	CITATIONS
1229	Resource use in the last year of life of prostate cancer patientsâ€”A register-based analysis. Prostate Cancer and Prostatic Diseases, 0, , .	3.9	0
1230	Preoperative pelvic floor muscle exercise for continence after radical prostatectomy: a systematic review and meta-analysis. Frontiers in Public Health, 0, 11, .	2.7	3
1231	Coâ€”designing an online treatment decision aid for men with lowâ€”risk prostate cancer: Navigate. BJUI Compass, 0, , .	1.3	0
1232	Emerging role of miRNA in prostate cancer: A future era of diagnostic and therapeutics. Gene, 2023, 888, 147761.	2.2	0
1233	<i>trans</i>-Cleavage of the CRISPR-Cas12a-aptamer system for one-step antigen detection. Chemical Communications, 0, , .	4.1	0
1234	Global viewpoints: updates on prostate cancer in <sc>Subâ€”Saharan</sc> Africa. BJU International, 2024, 133, 6-13.	2.5	1
1235	Evaluating the role of a <sup>99m</sup> Tc-HYNIC-PSMA SPECT scan following a negative bone scan in men with prostate cancer: a single-centre, retrospective cohort study. , 2023, 3, 116-120.		0
1236	Prostate cancer in India: Current perspectives and the way forward. , 0, 4, 8.		0
1237	Unveiling Disrupted Lipid Metabolism in Benign Prostate Hyperplasia, Prostate Cancer, and Metastatic Patients: Insights from a Colombian Nested Caseâ€”Control Study. Cancers, 2023, 15, 5465.	3.7	0
1238	A Web-Based Decision Aid for Informed Prostate Cancer Screening: Development and Pilot Evaluation. Journal of Korean Medical Science, 2023, 38, .	2.5	0
1239	Optimizing the diagnosis of prostate malignancy. Medic Ro, 2023, 4, 24.	0.0	0
1240	Interaction between smoking status and dietary selenium intake affects PSA: A cross-sectional study. Urologic Oncology: Seminars and Original Investigations, 2023, 41, 483.e1-483.e9.	1.6	0
1241	Efficacy of Treatment for Metastatic Hormone-Sensitive Prostate Cancer: An Umbrella Review of Systematic Reviews and Meta-Analyses. Cancers, 2023, 15, 5714.	3.7	0
1242	Long-term mortality among adults diagnosed with cancer during three decades in Finland. , 0, 1, .		0
1243	Redox State Modulatory Activity and Cytotoxicity of Olea europaea L. (Oleaceae) Leaves Extract Enriched in Polyphenols Using Macroporous Resin. Antioxidants, 2024, 13, 73.	5.1	0
1244	Prostate cancer antigen 3 test for prostate biopsy decision: a systematic review and meta analysis. Chinese Medical Journal, 2014, 127, 1768-1774.	2.3	0
1245	The Short- and Long-Term Anticipation of Prostate Cancer Incidence in Korea: Based on Social Aging Trends and Prostate-Specific Antigen Testing Rate during the Last Decade. Cancers, 2024, 16, 503.	3.7	0
1246	Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review. Cancers, 2024, 16, 523.	3.7	0

#	ARTICLE	IF	CITATIONS
1247	Wnt/ $\beta$ 2-catenin-driven EMT regulation in human cancers. Cellular and Molecular Life Sciences, 2024, 81, .	5.4	1
1248	Exposure to heavy metal elements may significantly increase serum prostate-specific antigen levels with overdosed dietary zinc. Ecotoxicology and Environmental Safety, 2024, 272, 116080.	6.0	0
1249	Redefining Rare Genitourinary Cancers: An Initiative Led by the Global Society of Rare Genitourinary Tumors. European Urology, 2024, 85, 414-416.	1.9	0
1250	Ultrasensitive prostate cancer marker PCA3 detection with impedimetric biosensor based on specific label-free aptamers. Biosensors and Bioelectronics: X, 2024, 18, 100462.	1.7	0
1251	Privacy Focused Classification of Prostate Cancer Using Federated Learning. Lecture Notes in Networks and Systems, 2024, , 265-281.	0.7	0
1252	PCC0208057 as a small molecule inhibitor of TRPC6 in the treatment of prostate cancer. Frontiers in Pharmacology, 0, 15, .	3.5	0